Composition for removing and inhibiting senescent cells, and uses thereof
A composition targeting senescent cells with compounds like KN046 or Pembrolizumab effectively addresses the limitations of existing treatments by selectively removing senescent cells and reducing their harmful effects, providing a safer therapeutic option for age-related diseases.
Patent Information
- Application Number
- PCT/KR2024/006112
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-04
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-07
AI Technical Summary
Current treatments for age-related diseases and disorders related to senescent cells, such as ABT-263/737, suffer from significant side effects like toxicity, necessitating the development of new compounds or compositions that can effectively remove senescent cells through a different mechanism.
A composition comprising compounds like KN046, AK104, Pembrolizumab, or secretions from cells treated with these compounds, which selectively target and eliminate senescent cells by increasing HMGN1 protein secretion, thereby blocking senescence-promoting factors and associated pathogenic effects.
The composition effectively removes senescent cells, reducing their harmful secretions and associated diseases, offering a therapeutic approach with potentially fewer side effects compared to existing treatments.
Smart Images

Figure PCTKR2024006112-APPB-IMG-000001 
Figure PCTKR2024006112-APPB-IMG-000002 
Figure PCTKR2024006112-APPB-IMG-000003
Abstract
Description
Composition for removing or inhibiting senescent cells and use thereof
[0001] This application claims priority to Korean Patent Application No. 10-2023-0058711, filed May 4, 2023, the entire disclosure of which is incorporated by reference into this application.
[0002] The present invention relates to a composition having the efficacy of eliminating senescent cells. The composition of the present invention comprises, as an active ingredient, a compound having excellent senescent cell-eliminating ability or a pharmaceutically acceptable salt thereof; a secretion of cells killed by treatment with such a compound or a pharmaceutically acceptable salt thereof; or a cell killed by treatment with such a compound or a pharmaceutically acceptable salt thereof. The present invention also relates to various uses of the composition of the present invention, particularly pharmaceutical uses.
[0003] Aging refers to the process by which humans, after a period of growth and development, gradually decline physically and cognitively, ultimately leading to death. Since the World Health Organization (WHO) designated old age as a disease (MG2A) in 2018, various research and development efforts and clinical trials are being conducted to treat (e.g., delay) aging.
[0004] In particular, through various research and development results, the target of aging is narrowing from 'individual' to 'cell'. Accordingly, it has been revealed that 'senescent cells' are the fundamental cause of various diseases and disorders related to aging. Senescent cells are generated in the human body due to various factors such as aging, drug side effects, stress, obesity, diabetes, wounds, transplants, and infections. These senescent cells are eliminated by the body's immune cells, but as aging progresses, immune cells may not function properly due to various reasons, or more fundamentally, immune cells themselves age, preventing them from functioning properly, ultimately leading to the accumulation of senescent cells in the body.
[0005] Accumulated senescent cells secrete a number of senescence-promoting factors as well as senescence-associated pathogenic factors, such as senescence-associated inflammation and senescence-associated fibrosis. The role of these senescence-associated secretory factors (SASP; senescence-associated secretory phenotype) is known to be (i) to gradually spread senescent cells by transforming surrounding normal cells into senescent cells, (ii) to promote structural and functional changes in the entire organs and tissues, (iii) to cause various underlying pathological phenotypes, such as chronic inflammation (immuno-aging) and fibro-aging, and (iv) to ultimately cause various senescence-associated diseases and disorders throughout the body.
[0006] Accordingly, various research and development efforts are underway to treat age-related diseases and disorders by eliminating senescent cells, much like cancer is treated by removing cancer cells (Robbins PD et al., Annual Review of Pharmacological Toxicology 61, 779-803, 2021). For example, while innovative anti-aging treatments such as ABT-263 / 737 have recently been reported, many side effects, including toxicity, remain problematic. Therefore, it is crucial to develop new compounds and / or compositions that eliminate senescent cells through mechanisms different from those of ABT-263 / 737.
[0007] Accordingly, the problem to be solved by the present invention is to provide a composition useful for removing senescent cells and a use of such a composition for removing senescent cells.
[0008] Another problem the present invention seeks to solve is to provide a composition that can improve, treat, or prevent various diseases and disorders associated with senescent cells by eliminating senescent cells by containing the active ingredient according to the present invention. In other words, another problem the present invention seeks to solve is to provide a use, preferably a pharmaceutical use, of the composition according to the present disclosure for improving, treating, or preventing diseases and disorders associated with senescent cells.
[0009] To achieve the above object, one aspect of the present invention provides a composition for removing senescent cells, comprising (a) a compound of Table 1 or 2 below or a pharmaceutically acceptable salt thereof; (b) a secretion of cells killed by treatment with the compound or a pharmaceutically acceptable salt thereof; or (c) cells killed by treatment with the compound or a pharmaceutically acceptable salt thereof. That is, one aspect of the present invention provides a use, preferably a pharmaceutical use, for removing senescent cells, comprising a compound of Table 1 or 2 below or a pharmaceutically acceptable salt thereof; a secretion of cells killed by treatment with the compound or a pharmaceutically acceptable salt thereof; or cells killed by treatment with the compound or a pharmaceutically acceptable salt thereof.
[0010] In one aspect of the present invention, the compounds of Table 1 or 2 below exhibit an action of increasing the secretion of HMGN1 (High Mobility Group Nucleosome Binding Domain 1) protein (HMG14) in senescent cells.
[0011]
[0012]
[0013]
[0014]
[0015]
[0016]
[0017]
[0018]
[0019]
[0020]
[0021]
[0022]
[0023]
[0024]
[0025]
[0026]
[0027]
[0028]
[0029]
[0030]
[0031]
[0032]
[0033]
[0034]
[0035]
[0036]
[0037]
[0038]
[0039]
[0040] A preferred embodiment of the present invention provides a composition for removing senescent cells, comprising as an active ingredient (a) a compound of Table 1 or a pharmaceutically acceptable salt thereof; (b) a secretion of cells killed by treatment with the compound of Table 1 or a pharmaceutically acceptable salt thereof; or (c) a cell killed by treatment with the compound of Table 1 or a pharmaceutically acceptable salt thereof.
[0041] In a preferred embodiment of the present invention, the compound having a senescent cell removal effect is at least one selected from the group consisting of compounds set forth in Table 1. For various purposes of the present invention, the compounds disclosed in Table 1 are more preferred.
[0042] In one aspect of the present invention, the CTLA4 inhibitor may include, for example, KN046, AK104, BMS-986288, MK-1308, ADG116, AGEN1181, ALPN-202, MEDI5752, MGD019, ONC-392, Alpha-D-Mannose, Fucose, Tremelimumab, Concatameric CTLA4Ig, CTLA-4-XTEN, AGEN1884, Ipilimumab, BCD-217, etc.
[0043] In one aspect of the present invention, the PD-1 inhibitor includes, for example, Pembrolizumab, Cemiplimab, Nivolumab, AMP-224, CBT-501, Dostarlimab, Sintilimab, Tislelizumab, Sasanlimab, INCSHR1210, Retifanlimab, Balstilimab, AK104, JTX-4014, Vopratelimab, RO7121661, 609A, ADPT01, AMG 404, APL-501, BI 754091, CDX-527, GSK2661380, IBI318, MEDI5752, MGD019, RG6139, 1,2,4-oxadiazole derivative 1, 1,2,4-oxadiazole derivative 2, 1,3,4-oxadiazole derivative 1, 1,3,4-oxadiazole derivative 2, Cyclic compound 1, Cyclic compound 2, Cyclic compound 3, PMID30107136-Compound-Example15 / 16, AUNP-12, PDR001, CC-90006, PMID30247903-Compound-General structure 13 / 14 / 15 / 16 / 17 / 20 / 21 / 22 / 23 / 24 / 25, BCD-217, BCD-100, PD-1 CAR T cells, etc. can be used. The structures of some of these compounds are as follows.
[0044]
[0045]
[0046]
[0047]
[0048] In one aspect of the present invention, the PD-L1 inhibitor may include, for example, Bavencio, KN046, CX-072, INCB86550, M7824, GS-4224, ALPN-202, BMS-986189, CA-170, FAZ053, IBI318, INBRX-105, KD033, LY3415244, CA-327, PMID30107136-Compound-Example1 / 2, PMID30247903-Compound-General structure5 / 6 / 7 / 8 / 9 / 10 / 12, Durvalumab, MEDI4736, MPDL-3280A, NM21-1480, PD-L1 CAR T cells, etc. The structures of some of these compounds are as follows.
[0049]
[0050]
[0051] In one aspect of the present invention, an anti-PD-L2 antibody or the like can be used as the PD-L2 inhibitor.
[0052] A composition for removing senescent cells according to the present invention, i.e., a composition comprising as an active ingredient (a) a compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, (b) a secretion of cells killed by treating Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, or (c) a cell killed by treating a compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, is useful for improving, treating, or preventing diseases and disorders related to senescent cells by removing senescent cells.
[0053] That is, one aspect of the present invention provides a use of the composition according to the present invention in a pharmaceutical, health functional food, cosmetic, or animal product for eliminating senescent cells. Another aspect of the present invention provides a use of the composition according to the present invention for improving, treating, or preventing diseases and disorders associated with senescent cells through eliminating senescent cells.
[0054] Accordingly, another aspect of the present invention provides a method for removing senescent cells, characterized in that the method comprises contacting senescent cells with a therapeutically, health-improvingly, or cosmetically effective amount of (a) a compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, (b) a secretion of cells killed by treating the compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, or (c) a cell killed by treating the compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, or administering or applying the same to a subject in need of treatment, improvement, or cosmetic effect of a disease or disorder associated with senescent cells.
[0055] Accordingly, another aspect of the present invention provides a method for improving, treating, or preventing a disease and / or disorder associated with senescent cells, characterized in that the method comprises contacting senescent cells with a therapeutically, health-improvingly, or cosmetically effective amount of (a) a compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, (b) a secretion of cells killed by treating the compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, or (c) a cell killed by treating the compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, or administering or applying the same to a subject in need of treatment, improvement, or cosmetic effect of the disease and disorder associated with senescent cells.
[0056] In one aspect of the present invention, contact with the senescent cells can be performed in vitro or ex vivo.
[0057] In one aspect of the present invention, the composition according to the present invention can be treated in vitro (or ex vivo) to tissues, organs or cells prior to transplantation or administration of the tissues, organs or cells, such as in the case of transplantation of tissues, organs or (stem) cells and administration of related therapeutic agents, and is used to remove senescent cells from the tissues, organs or cells to be transplanted or administered through such treatment.
[0058] As mentioned above, the composition of the present invention can be a pharmaceutical composition, a health functional food composition, a cosmetic composition, or a veterinary product composition, depending on its purpose. Accordingly, another aspect of the present invention provides the use of the active ingredients (a), (b), and / or (c) for the manufacture of a pharmaceutical, health functional food, cosmetic, or veterinary product useful for improving, treating, or preventing diseases and disorders associated with senescent cells.
[0059] In the present invention, aging may include, but is not limited to, natural aging due to the passage of time; aging due to stress such as anticancer drugs or radiation therapy; aging due to a diet high in fat, sugar, or salt, or nutritional deficiencies; aging due to infection with viruses, bacteria, or the like; and aging caused by physiological disturbances resulting from diseases such as obesity, diabetes, cancer, and fibrosis. In the present invention, aging refers to an internal phenomenon that promotes the generation and accumulation of senescent cells or activates the function of senescent cells.
[0060] The senescent cells described above may originate from a variety of cell types, including somatic cells, stem cells, and cells abnormally transformed by disease. The senescent cells may also be cells of organ tissues derived from the liver, kidney, spleen, brain, lungs, muscle, skin, fat, and other organs. The disease may be selected from the group consisting of inflammation, fibrosis, cancer, and the like.
[0061] The above senescent cells may exhibit any one or more of the following characteristics: (i) Cell division and growth are almost permanently suspended. (ii) Compared to non-senescent normal cells, the overall size of the cells, etc. is increased. In particular, the contents of lysosomes are increased, and abnormal mitochondria are increased. (iii) Nuclear structural proteins such as Lamin B1 and chromatin binding proteins such as HMGB1 are decreased. (iv) β-galactosidase (SA-β-gal) is expressed in accordance with aging. (v) Lipofuscin is produced. (vi) CDK (cyclin-dependent kinase) inhibitors such as p16 and p21 are activated and expressed in large amounts. (vii) As a persistent stress response, signal transduction systems such as p53 are activated according to the DNA damage response (DDR), and the expression of related target genes is regulated accordingly. In this way, it can be said that senescent cells commonly exhibit characteristics such as cessation of cell division and growth, and also exhibit senescence-associated markers such as SA-β-gal, lipofuscin, p16, p21, and p53 (see https: / doi.org / 10.1016 / j.tcb.2018.02.001).
[0062] The compound according to the present invention or a pharmaceutically acceptable salt thereof promotes the death of senescent cells or inhibits the expression and secretion of senescence-related markers, senescence-promoting factors, or senescence-related secretory factors. In one embodiment of the present invention, since these factors are expressed and secreted by senescent cells, the removal of senescent cells fundamentally blocks the expression and secretion of these factors. Furthermore, the removal of senescent cells allows an organism to maintain resilience and resistance to various stresses.
[0063] The above aging-associated secretory factors (SASPs) include various aging-associated pathological factors, such as IL1α, IL1β, IL6, IL10, MCP1, PAI1 VCAM1, MMP1, MMP2, MMP3, MMP12, MMP13, TGFβ, ACTA2, COL1A1, COL1A2, FN1, CXCL1, CXCL10, GM-CSF, GROα, GROβ, GROγ, IGFBP7, IL7, IL8, MIP1α, ENA78, GCP2, GITR, HGF, ICAM1, IGFBP2, IGFBP4, IGFBP5, IGFBP6, IL13, MCP4, MIF, MIP3α, MMP14, NAP2, PIGF, RANTES, sgp130, TIMP2, TRAILR3, Acrp30, Axl, bFGF, BLC, BTC, CTACK, EGFR, Fas, FGF7, GCSF, GDNF, HCC4, I309, IFNγ, IGFBP1, IGFBP3, IL11, IL15, IL2Rα, IL6R, ITAC, Leptin, LIF, MSPα, PAI2, PDGF-BB, SCF, SDF1, sTNF-RI, sTNF-RII, It may be TIMP-1, tPA, uPA, uPAR, VEGF, MCP3, IGF1, TGFβ3, MIP1, IL4, FGF7, PDGF-BB, IL16, BMP4, MDC, MCP4, IL10, TIMP1, ICAM1, Axl, CNTF, INFγ, EGF, BMP6, etc. (see http: / / www.saspatlas.com).
[0064] One aspect of the present invention is also based on the discovery that secretions or substances secreted from cells killed by treatment with a compound of Table 1 or Table 2 according to the present disclosure, preferably a compound of Table 1 or a pharmaceutically acceptable salt thereof, directly or indirectly induce and / or promote the death of senescent cells, or directly or indirectly block and / or inhibit the expression and secretion of senescence-associated markers, senescence-promoting factors, or senescence-associated secretory factors (SASP), and are useful for improving, treating, or preventing various diseases associated with senescent cells.
[0065] In the present invention, the term "secreted fluid" includes components secreted and released from cells killed by treatment with a compound according to the present disclosure or a pharmaceutically acceptable salt thereof. In one embodiment of the present invention, the "secreted fluid" may be a culture medium (e.g., a medium) in which cells are cultured. In another preferred embodiment of the present invention, the secreted fluid of the present invention may be a culture filtrate, a purified liquid, a concentrate, or a dried product thereof obtained by removing the compound of the present disclosure from a culture medium (e.g., a medium) in which cells are cultured. In the present invention, the "culture filtrate" may refer to a culture medium in which cells are inoculated into a medium, cultured by treating the compound of the present disclosure, and then removing the cells and compounds. In one embodiment of the present invention, the culture filtrate may be obtained by (ultra)centrifuging a culture medium from which cells, compounds, etc. have been removed, and separating and purifying the obtained supernatant using (ultra)filtration, chromatography, etc. When administered to a human body or the like, a culture filtrate containing the secreted fluid or killed cells that produce the secreted fluid may be administered. In one aspect of the present invention, the secretion is contained in a culture filtrate or is produced and secreted from dead cells.
[0066] That is, one aspect of the present invention is based on the fact that (other) senescent cells can be suppressed or removed using (a) a compound or a salt thereof having an effect of killing or inhibiting senescent cells, (b) a secretion from a dying senescent cell, and / or (c) the dying senescent cell itself. Although the death of senescent cells can also be induced through the activation of an immune response in which the secretion (substance) and the dying senescent cell activate and / or recruit immune cells in the body, the present invention is not limited to this theoretical mechanism.
[0067] In the present invention, a "pharmaceutically acceptable salt" may be an acid addition salt formed by a pharmaceutically acceptable free acid. The free acid may be an inorganic acid or an organic acid. In this case, the inorganic acid may be hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, hydrobromic acid, etc., and the organic acid may be acetic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, oxalic acid, benzoic acid, embonic acid, aspartic acid, glutamic acid, etc. The acid addition salts can be prepared by conventional methods, for example, by dissolving the compound of the present disclosure in an excess of an aqueous acid solution and precipitating the salt using a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile. In addition, when the compound of the present disclosure is acidic, the pharmaceutically acceptable salts can form base addition salts with various cations. Examples of such bases include alkali metal or alkaline earth metal salts, and for example, calcium, magnesium, sodium, lithium, zinc, potassium and iron salts, in particular. The alkali metal or alkaline earth metal salts can be obtained by dissolving the compound of the present disclosure in an excess of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the undissolved compound salt, and then evaporating and drying the filtrate. In addition, the base addition salt may be an organic salt such as trimethylamine, triethylamine, dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, procaine, meglumine, ethylenediamine, choline, N,N-dibenzylethylenediamine, benzathine, benetamine, pyridine, picoline, quinoline, isoquinoline, tetramethylammonium, tetraethylammonium, benzyltrimethylammonium, benzyltriethylammonium, benzyltributylammonium, methyltrioctylammonium, tetrabutylammonium, arginine, lysine, histidine, etc.
[0068] As used herein, the term "compound of the present invention" is meant to include not only each compound of Table 1 or Table 2, but also isotopic variants, prodrugs, clathrates, hydrates, solvates, or polymorphs thereof. In addition, the term "compound of the present invention" is meant to include pharmaceutically acceptable salts of the compounds of the present invention, unless a pharmaceutically acceptable salt thereof is mentioned. In one embodiment, the compounds of the present invention can exist as stereomerically pure compounds (e.g., substantially free of other stereoisomers (e.g., 85% ee or more, 90% ee or more, 95% ee or more, 97% ee or more, or 99% ee or more)). That is, if the compound of the present invention or a salt thereof is a tautomeric isomer and / or stereoisomer (e.g., a geometrical isomer and a conformational isomer), each of the separated isomers and mixtures thereof are also included in the scope of the compound of the present invention. If the compound of the present invention or a salt thereof has an asymmetric carbon in its structure, their optically active compounds and racemic mixtures are also included in the scope of the compound of the present invention.
[0069] As used herein, the term "isotopic variant" means a compound that contains an unusual ratio of isotopes at one or more atoms constituting the compound. For example, an isotopic variant of a compound may be radioactively labeled, for example, a hydrogen atom may be selected from hydrogen, deuterium, and tritium, and a carbon-13 ( 13 C), nitrogen-15( 15 N) may contain the following.
[0070] If any compound (prodrug) is cleaved in the body to produce a compound of the present disclosure or a salt thereof, such compound is also included within the scope of the present invention. As used herein and unless otherwise indicated, the term "prodrug" means a compound of the present invention that can be hydrolyzed, oxidized, and otherwise reacted under biological conditions (either in vitro or in vivo) to provide an active compound, particularly a compound of the present invention. Examples of prodrugs include, but are not limited to, compounds that contain a biohydrolyzable moiety, such as biohydrolyzable amides, biohydrolyzable esters, biohydrolyzable carbamates, biohydrolyzable carbonates, biohydrolyzable ureides, and biohydrolyzable phosphate analogs, which undergo biohydrolyzation to produce a compound of the present invention. Preferably, the prodrug of a compound having a carboxylic functional group is a lower alkyl ester of a carboxylic acid. Carboxylic esters are typically formed by esterifying a portion of the carboxylic acid present in the molecule. Prodrugs can be readily prepared using methods well known in the art.
[0071] As used herein, the term "polymorph" means a solid crystalline form of a compound of the present invention or a complex thereof. Different polymorphs of the same compound exhibit different physical, chemical, and / or spectral properties. Differences in physical properties include, but are not limited to, stability (e.g., heat or light stability), compressibility and density (important for formulation and product manufacturing), and dissolution rate (which may affect bioavailability). Differences in stability may result from changes in chemical reactivity (e.g., differential oxidation, such as faster discoloration of one polymorph than of another), mechanical properties (e.g., tablet fragments stored as a kinetically favored polymorph transform to the thermodynamically more stable polymorph), or both (tablets of one polymorph are more susceptible to degradation at high humidity). Different physical properties of polymorphs may affect their processing. For example, one polymorph may be more likely to form solvates or more difficult to filter or wash than another polymorph, for example due to its shape or particle size distribution.
[0072] The term "solvent compound" as used herein refers to a compound of the present invention or a pharmaceutically acceptable salt thereof comprising a stoichiometric or non-stoichiometric amount of a solvent bound by non-covalent intermolecular forces. Preferred solvents are volatile, non-toxic, and can be administered to humans in very small amounts.
[0073] The term "hydrate" as used herein means a compound of the present invention or a pharmaceutically acceptable salt thereof comprising a stoichiometric or non-stoichiometric amount of water bound by non-covalent intermolecular forces.
[0074] The term "clathrate" as used herein means a compound of the present invention or a salt thereof in the form of a crystal lattice that includes spaces (e.g., channels) that confine guest molecules (e.g., solvent or water).
[0075] According to the present invention, (a) a compound of Table 1 or Table 2, preferably a compound of Table 1 or a pharmaceutically acceptable salt thereof, (b) a secretion of a cell killed by treatment with a compound of Table 1 or Table 2, preferably a compound of Table 1 or a pharmaceutically acceptable salt thereof; or (c) a cell killed by treatment with a compound of Table 1 or Table 2, preferably a compound of Table 1 or a pharmaceutically acceptable salt thereof, has the effect of killing senescent cells or blocking the function of senescent cells, and is useful for improving, treating, or preventing various diseases and disorders related to senescent cells.
[0076] In one aspect of the present invention, diseases and disorders that can be improved, treated or prevented by removing senescent cells or inhibiting the action of senescent cells are:
[0077] Proliferative diseases and disorders such as cancer, pre-cancerous / pre-malignant condition, resistance, malignancy, relapse, and metastasis;
[0078] Arthritis, osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, degenerative joint disorder, degenerative articular cartilage, inflammatory bowel disease, ulcerative colitis, Crohn's disease, stomatitis, mucositis, oral mucositis, pancreatitis, tendinopathy, tendinosis, tendonitis or tendinitis, synovitis, tenosynovitis, inflammation-aging, amplified hyperinflammation, cytokine release / storm syndrome, COVID-19 infection, COVID-19 complication, femoroacetabular impingement syndrome, tunnel syndrome, meniscus tear, meniscus derangement, meniscus lesion, meniscus disorder, sepsis, HIV infection, AIDS, rhinovirus infection, inflammatory response syndrome after surgery, spondylarthritis,Inflammatory or autoimmune diseases and disorders, such as autoimmune encephalomyelitis and common variable immunodeficiency;
[0079] Neurodegenerative disease, dementia, Alzheimer's disease, memory disorder, cognitive decline dysfunction, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis / Lou Gehrig's disease, motor neuron disease, primary lateral sclerosis, progressive muscular atrophy, lower motor neuron disease, spinal muscular atrophy, progressive bulbar paralysis, pseudobulbar palsy, post-polio syndrome, spastic paraplegia, Neurological diseases and disorders such as progressive supranuclear palsy, spinal cord injury, chronic pain, allodynia, anxiety, depression, schizophrenia, neuropsychiatric dysfunction, post-traumatic stress disorder, Gulf war illness, and sleep disorders;
[0080] Metabolic diseases and disorders such as obesity, diabetes, diabetic ulcer, osteoporosis, intestinal bowel disease (intestinal bowel microbiome disorder), lipodystrophy, adipose atrophy, hypogonadism, and various metabolic syndromes;
[0081] Atherosclerosis, heart failure, congestive heart failure, cardiomyopathy, heart functional disorder, cardiac dysfunction, angina pectoris, endocarditis, mitral valve prolapse, myocardial infarction, cardiomyocyte hypertrophy, loss of cardiac stress tolerance, idiopathic dilated cardiomyopathy, aneurysm, aortic aneurysm, coronary artery aneurysm, brain aneurysm, vascular hyporeactivity / calcification, age-related vascular dysfunction, arteriovenous fistula Cardiovascular diseases and disorders such as fistula, stenosis, renal artery stenosis, carotid artery stenosis, neointimal hyperplasia, hypertension, stroke, thrombosis, coagulation disorders, spontaneous cerebral microhemorrhages, dyslipidemia, atrial fibrillation, arrhythmia, and diabetic cardiomyopathy;
[0082] Chronic obstructive pulmonary disease, emphysema, chronic pneumonia, bronchiectasis, age-related pulmonary dysfunction, respiratory failure, pulmonary function insufficiency, hyperoxic lung injury, bronchopulmonary dysplasia, respiratory distress syndrome, pulmonary hypertension, asthma, pneumonia, viral pneumonia, interstitial pneumonia, cryptogenic organizing pneumonia, idiopathic pleuroparenchymal fibroelastosis, hypersensitivity pneumonitis, Lung diseases and disorders such as granulomatous-lymphocytic interstitial lung disease and chronic bronchitis;
[0083] Kidney diseases and disorders such as chronic kidney disease, nephropathy, renal failure / dysfunction, glomerulosclerosis, diabetic nephropathy, diabetic chronic kidney disease, polycystic kidney disease, immunoglobulin A nephropathy, kidney stone disease (nephrolithiasis), nephronophthisis, lupus nephritis, tubulointerstitial disease, and renal tubulointerstitial injury;
[0084] Liver diseases and disorders such as cirrhosis, liver fibrosis, hepatitis, hepatopathy, fatty liver, nonalcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, primary biliary cirrhosis, cholangitis, primary sclerosing cholangitis, biliary atresia, hepatic encephalopathy, and biliary injury;
[0085] Ocular diseases and disorders such as cataracts, glaucoma, age-related macular degeneration, macular degeneration, macular edema, retinal degenerative diseases, age-related vision loss, retinopathy, diabetic retinopathy, diabetic macular edema, dry eye disease, hyperemia, retinal microaneurysm, retinal microangiopathy, Fuchs endothelial dystrophy, corneal dystrophies, and birdshot uveitis;
[0086] Skin aging, epidermal atrophy, loss of elasticity, wrinkles, skin photoaging, hair loss (allopecia), skin naevi, liver spots, pigmentation, hyperpigmentation, melasma, blemishes, keloids, damage / wound healing disorders, psoriasis, lupus, systemic lupus erythematosus, dermatopolymyositis, immunobullous disease, pemphigus, bullous pemphigoid, blisters, warts, Human papillomavirus infection, dermatitis, eosinophilic dermatoses, atopic dermatitis, skin lymphoma, erythroderma, lichen planus, lichenoid dermatosis, febrile neutrophilic dermatosis, rosacea, dermatofibroma, keratosis pilaris, herpes, pruritus, sensory defect, eczema, eruption, urticaria, vitiligo, senescence in gingival tissues, dyskeratosis congenita,Skin diseases and disorders such as ichthyosis vulgaris, actinic keratosis, photosensitivity, and photodermatoses;
[0087] Various stem cell / bone marrow regenerative maintenance diseases and disorders, such as bone marrow stem cell functional disorder; various organ / tissue regenerative maintenance diseases and disorders, such as liver organ regeneration, kidney organ regeneration, heart organ regeneration, and neuroregeneration; immune regulation diseases and disorders, such as myelodysplastic syndromes, myelopathy, and inflammation; various organ / tissue damage and functional decline, such as sarcopenia; diseases and disorders related to regenerative maintenance;
[0088] Transplant-related diseases and disorders, including graft versus host disease, stem cell transplantation complications, bone marrow transplantation complications, cardiac organ transplantation complications, renal organ transplantation complications, corneal allograft rejection, chronic allograft nephropathy, and various stem cell / bone marrow / organ / tissue / cell transplantation diseases and disorders, and various foreign body / material transplant diseases and disorders, such as foreign body response;
[0089] Fibrotic diseases and disorders, including idiopathic pulmonary fibrosis, pulmonary fibrosis, cystic fibrosis, renal fibrosis, tubulointerstitial fibrosis, liver fibrosis, cardiac fibrosis, pancreatic fibrosis, retroperitoneal fibrosis, mediastinal fibrosis, uterine fibrosis, biliary fibrosis, oral submucous fibrosis, muscle fibrosis, neurofibroma, myelofibrosis, and fibrodysplasia ossificans progressiva;
[0090] Sclerotic diseases and disorders such as systemic sclerosis, scleroderma, and multiple sclerosis;
[0091] β-galactosidase-related diseases and disorders, such as progerias, Hutchinson-Gilford progeria syndrome, Werner syndrome, Bloom syndrome, Marfan syndrome, Wiedemann-Rautenstrauch syndrome, Rothmund-Thomson syndrome, Cockayne syndrome, Down syndrome, and dyskeratosis congenita;
[0092] Reduced lifespan / healthspan, frailty, inflammaging, chronic inflammation, late-life depression, sarcopenia, muscular dystrophy, muscle fibrosis, myotonic dystrophy type 1, amyotonia congenita, fibromyalgia, rotator cuff tear, osteoporosis, skeletal disorder, ataxia, wound healing disorder, delayed fracture healing, lipodystrophy, adipose atrophy, intervertebral disc degeneration, lumbar herniated disc Other geriatric diseases and disorders, such as intervertebral disc, kyphosis, low back pain, fibrodysplasia ossificans progressiva, menopause, endometriosis, polycystic ovary syndrome, tremor, urinary incontinence, urination disorder, prostatic hypertrophy, splenomeglay, hearing loss, olfactory dysfunction, ovarian aging, and periodontal disease;
[0093] Initial damage and subsequent side effects and sequelae caused by various acute and chronic stressors including anticancer drugs such as radiation / chemo / targeted / immunotherapy, drugs / substances with strong toxicity and side effects, physiological disturbances such as obesity / diabetes, high-fat / high-sugar / high-salt diets, hemorrhagic shock, myocardial infarction, hypoxia, ischemia and reperfusion injury, nutritional deficiencies, war, accidents, smoking, infections with viruses / bacteria such as HIV, surgery, foreign transplantation, inflammation, tissue wounds, hyperthermia, etc., and diseases and disorders caused by these, such as fatigue / weakness / weakness (fatigue), weight loss, physical inactivity, ataxia, cachexia, boredom, depression, anxiety, neuropsychiatric dysfunction, lethargy, stress neurosis, Anorexia nervosa, syncope, panic disorder, chronic inflammation, stomatitis, mucositis, oral mucositis, thrombocytopenia, radiation ulcers, bone marrow disorder, anemia, immune disorder, hormone disorder, menopause, nausea, vomiting, diarrhea, hepato / nephrocomplication, hepato- / nephro- / cardio- / gastrointestinal / ovarian / vascular / skin toxicity, heart functional disorder,Cardiomyopathy, congestive heart failure, peripheral neuropathy, hair loss (allopecia), dermatitis, rash, pain, fluid retention, urticaria, hyperpigmentation, lipodystrophy, adipose atrophy, bone loss, osteoporosis, infertility, oligospermia, abnormal embryo implantation and placentation, reduced reproductive outcome from in vitro fertilization, preeclampsia, pregnancy loss (miscarriage), cognitive decline dysfunction. Various age-related diseases and disorders such as cancer relapse, metastasis, vision loss, hearing loss, ovarian injury, hyposalivation, pulmonary fibrosis, and blue light toxicity;
[0094] Diseases and disorders found in a small population in relation to the above diseases and disorders, such as acquired lipodystrophy, acromegaly, acute respiratory distress syndrome, Alexander disease, alpha-1 antitrypsin deficiency, amyloidosis, autoimmune hemolytic anemia, aplastic anemia, anencephaly, antiphospholipid syndrome, Takayasu arteritis, infectious arthritis, ataxia with vitamin E deficiency, Behcet's syndrome, benign paroxysmal positional vertigo, beta thalassemia, Biliary atresia, Bloom syndrome, CDKL5 deficiency disorder, chronic granulomatous disease, common variable immune deficiency, corneal dystrophies, Costello syndrome, creatine transporter deficiency, cystic fibrosis, cytochrome C oxidase deficiency, cytomegalovirus infection, Danon disease, dengue fever,Duchenne muscular dystrophy, dyskeratosis congenita, herpe simplex encephalitis, Erdheim-Chester disease, Fanconi anemia, fibrodysplasia ossificans progressiva, focal segmental glomerulosclerosis, Friedreich's ataxia, frontotemporal degeneration, glucose-6-phosphate dehydrogenase deficiency, graft versus host disease, hepatic encephalopathy, Hermansky-Pudlak syndrome, Hodgkin's disease, Huntington's disease, Hutchinson-Gilford progeria syndrome, progeria, hypoplastic left heart syndrome, idiopathic pulmonary fibrosis, immunoglobulin A nephropathy, immune thrombocytopenia, Kawasaki disease, Langerhans cell histiocytosis, leprosy, Li-Fraumeni syndrome, limb-girdle muscular dystrophies,lymphangioleiomyomatosis, malaria, Marfan syndrome, measles, multiple myeloma, multiple sclerosis, muscular dystrophy (Becker), myelodysplastic syndromes, Myhre syndrome, myotonic dystrophy, nontuberculous mycobacterial lung disease, pneumocystis pneumonia, primary biliary cholangitis, primary sclerosing cholangitis, pulmonary arterial hypertension, Rett syndrome, Rothmund-Thomson syndrome, Scleroderma, sialadenitis, ulcerative colitis, Werner syndrome, Wiedemann rautenstrauch syndrome, abdominal aortic aneurysm, ankylosing spondylitis, Ankyrin-B syndrome, anterior uveitis, PASLI disease, Down syndrome, coronary artery aneurysm, dilated cardiomyopathy, doxorubicin-induced cardiomyopathy, eclampsia,High molecular weight kininogen deficiency, interstitial cystitis, interstitial lung disease, Kindler syndrome, Lewy body dementia, lupus, lupus nephritis, neural tube defects, neuroferritinopathy, Nijmegen breakage syndrome, nonalcoholic steatohepatitis, oral leukoplakia, oral submucous fibrosis, paraplegia, Parkinson's disease, peripartum cardiomyopathy, psoriasis, silicosis, Sjogren syndrome, tuberous sclerosis complex, xeroderma pigmentosum, sickle cell disease, acute myeloid leukemia, craniopharyngioma, glioblastoma, glioma, hepatocellular carcinoma, malignant melanoma, small cell lung cancer, thyroid cancer, acute monoblastic leukemia, diffuse large B-cell lymphoma,Examples include, but are not limited to, rare diseases and disorders (age-related), such as oral squamous cell carcinoma.
[0095] In a preferred embodiment of the present invention, the proliferative disease and disorder is cancer. In a preferred embodiment of the present invention, the inflammatory or autoimmune disease and disorder is arthritis, osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, degenerative cartilage disease, or kyphosis. In a preferred embodiment of the present invention, the neurological disease and disorder is a degenerative brain disease (dementia, Alzheimer's disease, memory loss, (mild) cognitive impairment, etc.). In a preferred embodiment of the present invention, the metabolic disease and disorder is obesity, diabetes and diabetic complications (diabetic ulcer, diabetic retinopathy, diabetic cardiomyopathy, diabetic nephropathy, etc.), or senile bone disease (osteoporosis, fracture healing disorders, alveolar bone loss, periodontal disease, etc.). In a preferred embodiment of the present invention, the cardiovascular disease and disorder is atherosclerosis, aortic aneurysm, coronary aneurysm, cerebral aneurysm, senile vascular dysfunction, decreased cardiac load resistance, cardiac hypertrophy, myocardial infarction, heart failure, or hypertension. In a preferred embodiment of the present invention, the pulmonary disease and disorder is idiopathic pulmonary fibrosis, chronic pulmonary inflammation, pulmonary dysfunction, pulmonary fibrosis, chronic obstructive pulmonary disease, or emphysema. In a preferred embodiment of the present invention, the renal disease and disorder is nephropathy, renal failure, glomerulosclerosis, or chronic kidney disease. In a preferred embodiment of the present invention, the liver disease and disorder is fatty liver (alcoholic / non-alcoholic fatty liver disease, hepatic steatosis, etc.), hepatopathy, hepatic fibrosis, cirrhosis, hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, or bile duct damage. In a preferred embodiment of the present invention, the ocular disease or disorder is a cataract, or a retinal degenerative disease (age-related macular degeneration, macular edema, retinopathy, etc.). In a preferred embodiment of the present invention, the skin disease or disorder is skin aging, epidermal atrophy, loss of elasticity, wrinkles, nevi, spots, pigmentation, freckles, blemishes, hair loss, or wound healing disorder. In a preferred embodiment of the present invention, the fibrotic disease or disorder is retroperitoneal fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis, or liver fibrosis.In a preferred embodiment of the present invention, the sclerosing disease and disorder is systemic sclerosis (idiopathic pulmonary fibrosis, scleroderma). In a preferred embodiment of the present invention, the other geriatric diseases and disorders are frailty, sarcopenia, muscular dystrophy, lipoatrophy, age-related inflammation, or geriatric depression. In a preferred embodiment of the present invention, the side effects and sequelae due to stress and the age-related diseases and disorders resulting therefrom are fatigue and weakness, lethargy, weight loss, hepatotoxicity, nephrotoxicity, thrombosis, hair loss, or bone marrow dysfunction (myelodysplastic syndrome, myelopathy, bone marrow transplant failure, anemia, etc.). In a preferred embodiment of the present invention, the rare disease is lipodystrophy, idiopathic pulmonary fibrosis, Lewy body dementia, or nonalcoholic steatohepatitis.
[0096] In another preferred embodiment of the present invention, diseases and disorders that can be improved, treated or prevented by removing senescent cells or inhibiting the action of senescent cells include cancer (which is inhibited and treated by removing senescent cancer cells through prosenescence anti-cancer therapy, and thereby includes not only cancer but also early cancer, prevention, recurrence, metastasis, resistance, malignancy or sequelae of cancer), inflammation (inflammation-aging (immuno-senescence, senescence-associated inflammation) caused by senescent cells, and includes persistent, progressive chronic and degenerative inflammation observed in the elderly due to this or hyper-amplified inflammation accompanied by cytokine storm observed in the elderly due to infection with viruses, etc.), fibrosis and cirrhosis (including fibrosis and cirrhosis in the liver, lungs or kidneys, etc.), geriatric diseases (e.g., frailty (including decline in activity, endurance, muscle strength and / or grip strength), sarcopenia, osteoporosis or lipoatrophy), kidney damage, liver damage, skin Diseases and disorders related to aging (including wrinkles, loss of elasticity, hair loss, deterioration of hair texture, freckles, blemishes, moles, spots, spots, pigmentation, warts, hives, deterioration of pores, and wound healing disorders), side effects and sequelae caused by stress due to anticancer drugs or obesity (including fatigue, weakness, weight loss, anxiety, depression, lethargy, fatty liver, etc.).
[0097] In relation to the above frailty, frailty is a specific disease, for example, recently assigned the R54 code, and is characterized by symptoms such as old-age fatigue, weakness, asthenia, inactivity, muscle weakness, and gait disturbance, which occur with or without cognitive and memory impairment due to aging. Frailty can be analyzed by symptom index (https: / en.wikipedia.org / wiki / Frailty_syndrome).
[0098] The term "treatment" as used herein means any action (alleviate, reverse or treat) that improves, ameliorates or beneficially alters the symptoms of aging-related diseases and disorders by administering the active ingredient of the present invention, "prevention" means any action (prevent, inhibit or delay) that blocks, suppresses or delays the progression of aging-related diseases and disorders by administering the composition according to the present invention, and "elimination" of senescent cells means any action that inhibits the function of senescent cells, such as death of senescent cells.
[0099] In one aspect of the present invention, (a) a compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, (b) a secretion of cells killed by treatment with a compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, or (c) a cell killed by treatment with a compound of Table 1 or Table 2 (preferably, Table 1) or a salt thereof may be administered or applied to a patient in a therapeutically, cosmetically, or pharmaceutically effective amount.
[0100] One aspect of the present invention provides a method for improving, treating, or preventing diseases and disorders associated with senescent cells, comprising contacting senescent cells with a therapeutically, cosmetically, or pharmaceutically effective amount of a substance that increases the secretion of HMGN1 (High Mobility Group Nucleosome Binding Domain 1) protein (HMG14) in senescent cells, or administering or applying the substance to a subject in need of improvement, treatment, or prevention of diseases and disorders associated with senescent cells. In this method, the 'substance that increases the secretion of HMG14' and the 'diseases and disorders associated with senescent cells' are the same as described above.
[0101] Here, the term "therapeutically effective amount" or "pharmaceutically effective amount" refers to an amount of a compound or composition that is effective in preventing or treating a target disease, and is sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment, and does not cause side effects. In addition, the "effective amount" refers to an amount sufficient to inhibit or reduce the activity of senescent cells in an aging-related disease, either in vitro or in vivo. The level of the effective amount may be determined based on factors including the patient's health condition, the type and severity of the disease, the activity of the drug, the sensitivity to the drug, the method of administration, the time of administration, the route of administration and the excretion rate, the duration of treatment, the drugs used in combination or concurrently, and other factors well known in the medical field.
[0102] One aspect of the present invention also provides a method for removing senescent cells by contacting the senescent cells in vivo or ex vivo with (a) a compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, (b) a secretion of cells killed by treating the compound of Table 1 or Table 2 (preferably, Table 1) or a pharmaceutically acceptable salt thereof, or (c) a cell killed by treating the compound of Table 1 or Table 2 (preferably, Table 1) or a salt thereof.
[0103] In one aspect of the present invention, the composition of the present invention can be used for the purposes described above (i.e., for removing senescent cells and / or for improving, treating or preventing diseases and disorders associated with senescent cells) by combining at least one active ingredient (different from the first active ingredient) selected from the group consisting of Roxadustat, Dexmedetomidine, 5-aminosalicylic acid, Pioglitazone, Rosiglitazone, Setanaxib, and an immune checkpoint inhibitor as a second active ingredient. That is, the composition of the present invention is more preferable for the purposes of the present invention when combined with at least one second active ingredient (different from the first active ingredient) selected from the group consisting of Roxadustat, Dexmedetomidine, 5-aminosalicylic acid, Pioglitazone, Rosiglitazone, Setanaxib, and an immune checkpoint inhibitor.
[0104] In one aspect of the present invention, the second active ingredient may be included within the composition of the present invention, or may be administered simultaneously or sequentially as a separate composition (formulation). Accordingly, one aspect of the present invention provides a kit or formulation for removing senescent cells, comprising the composition according to the present invention (first active ingredient) and the second active ingredient.
[0105] Accordingly, another aspect of the present invention also provides a method for removing senescent cells, comprising contacting senescent cells with a composition according to the present invention and one or more additional second active ingredients (selected from the group consisting of Roxadustat, Dexmedetomidine, 5-aminosalicylic acid, Pioglitazone, Rosiglitazone, Setanaxib, and an immune checkpoint inhibitor) simultaneously or sequentially, or administering or applying to a subject in need of ameliorating, treating, or preventing a disease or disorder associated with senescent cells. Another aspect of the present invention also provides a method for ameliorating, treating, or preventing a disease or disorder associated with senescent cells, comprising contacting senescent cells with a composition according to the present invention and one or more additional second active ingredients simultaneously or sequentially, or administering or applying to a subject in need of ameliorating, treating, or preventing a disease or disorder associated with senescent cells.
[0106] In such combination or combination method, the second active ingredient is at least one selected from the group consisting of Roxadustat, Dexmedetomidine, 5-aminosalicylic acid, Pioglitazone, Rosiglitazone, Setanaxib, and an immune checkpoint inhibitor, wherein the immune checkpoint inhibitor may be at least one of the aforementioned CTLA4 inhibitor, PD-1 inhibitor, PD-L1 inhibitor, and PD-L2 inhibitor. In this case, the compound included in the composition according to the present invention, which is used or combined with the second active ingredient, and the compound treated to the cell to obtain the secreted fluid of the cell according to the present invention or the dead cell are different compounds from the second active ingredient.
[0107] In such combination or combined methods, the composition of the present invention and the second active ingredient are administered in any order or simultaneously. If simultaneously, the composition of the present invention and the second active ingredient are optionally provided in a single, unified form, or multiple forms (e.g., as one tablet or two separate tablets).
[0108] Furthermore, in these combination or combined methods, the combination methods, compositions, and formulations are not limited to the use of just two agents, and multiple therapeutic combinations are also envisioned. The dosage regimen for treating, preventing, or ameliorating the pathological condition(s) may be arbitrarily modified based on various factors. These factors include the subject's age, weight, sex, diet, and medical condition, as well as any disorders the subject suffers from.
[0109] The pharmaceutical formulations comprising the combination therapy disclosed herein are optionally combined formulations or separate formulations primarily intended for simultaneous administration. The pharmaceutical formulations comprising the combination therapy may also be administered sequentially as one of the formulations administered in a two-step administration regimen. A two-step administration regimen may require sequential administration of the active agents or spaced administration of separate active agents. The time interval between multiple administration steps may range from several minutes to several hours, depending on the characteristics of each pharmaceutical formulation, such as potency, solubility, bioavailability, plasma half-life, and the kinetic profile of the pharmaceutical formulation. Circadian variation in target molecule concentrations is used to determine the optimal dosing interval.
[0110] For the treatment of the diseases or conditions described above, the active ingredients and / or compositions described herein may be administered as follows.
[0111] Oral administration
[0112] The active ingredient of the present invention can be administered orally, with the term "oral" encompassing swallowing. Oral administration allows the active ingredient of the present invention to enter the gastrointestinal tract, or, for example, be absorbed directly into the bloodstream through the mouth, as in buccal or sublingual administration.
[0113] Suitable compositions for oral administration may be in the form of solids, liquids, gels, or powders, and may have dosage forms such as tablets, lozenges, capsules, granules, or powders.
[0114] Liquid formulations may include solutions, syrups, and suspensions, and these liquid compositions may be contained within soft or hard capsules. These formulations may include pharmaceutically acceptable carriers, such as water, ethanol, polyethylene glycol, cellulose, or oil. The formulations may also include one or more emulsifying and / or suspending agents.
[0115] In tablet formulations, the active ingredient, the effective ingredient, may be present in an amount of from about 0.05% to about 95% by weight of the total weight of the tablet, more typically from about 2% to about 50% by weight of the formulation. The tablet may also contain a disintegrant, which comprises from about 0.5% to about 35% by weight, more typically from about 2% to about 25% by weight of the formulation. Examples of disintegrants include, but are not limited to, lactose, starch, sodium starch glycolate, crospovidone, croscarmellose sodium, maltodextrin, or mixtures thereof.
[0116] Suitable lubricants included for manufacturing the tablets may be present in an amount of about 0.1 wt% to about 5 wt%, and talc, silicon dioxide, stearic acid, calcium, zinc or magnesium stearate, sodium stearyl fumarate, etc. may be used as lubricants, but the present invention is not limited to the types of these additives.
[0117] Gelatin, polyethylene glycol, sugar, gum, starch, polyvinylpyrrolidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, etc. can be used as binders for manufacturing into tablets, and mannitol, xylitol, lactose, dextrose, sucrose, sorbitol, starch, microcrystalline cellulose, etc. can be used as suitable diluents for manufacturing into tablets, but the present invention is not limited to the types of these additives.
[0118] Solubilizing agents that may optionally be included in the tablet may be used in an amount of about 0.1 wt% to about 3 wt% based on the total weight of the tablet, and examples thereof include polysorbates, sodium lauryl sulfate, sodium dodecyl sulfate, propylene carbonate, diethylene glycol monoethyl ether, dimethyl isosorbide, polyoxyethylene glycolated natural or hydrogenated castor oil, HCOR. TM (Nikkol), oleic acid ester, gelucire TM ), caprylic / caprylic acid mono / diglycerides, sorbitan fatty acid esters, solutol HS TM Although these may be used in the pharmaceutical composition according to the present invention, the present invention is not limited to the specific types of these solubilizing agents.
[0119] Parenteral Administration
[0120] The active ingredient of the present invention can be administered directly into the bloodstream, muscle, or internal organs. Suitable methods for parenteral administration include intravenous, intramuscular, subcutaneous intraarterial, intraperitoneal, intrathecal, and intracranial injections. Suitable devices for parenteral administration include injectors (including needle and needle-less syringes) and infusion methods.
[0121] Most parenteral formulations are liquid compositions, which are aqueous solutions containing the active ingredient, salt, buffer, isotonic agent, etc. according to the present invention.
[0122] Parenteral formulations can also be prepared in a dry form (e.g., lyophilized) or as a sterile non-aqueous solution. These formulations can be used with a suitable vehicle, such as sterile water. Solubility-enhancing agents can also be used in the preparation of parenteral solutions.
[0123] Topical Administration
[0124] The active ingredient of the present invention can be administered topically, either through the skin or transdermally. In particular, when the composition of the present disclosure is a cosmetic composition, a topical formulation is preferred. Formulations for topical administration include lotions, solutions, creams, gels, hydrogels, ointments, foams, implants, patches, and the like. Pharmaceutically or cosmetically acceptable carriers for topical formulations may include water, alcohol, mineral oil, glycerin, polyethylene glycol, and the like.
[0125] If the composition of the present invention is a cosmetic composition, it may be in the liquid formulation mentioned above.
[0126] Other various administration methods
[0127] In addition to the above method, various administration methods are included, and further, the composition of the present invention can be used to remove senescent cells externally, such as in cases of exogenous transplantation of tissues / organs or (stem) cells, and administration of therapeutic agents.
[0128] The active ingredient and composition according to the present invention can fundamentally block and suppress the expression and secretion of various aging-related pathological factors secreted from senescent cells by removing them. In addition, the secretion from cells whose death is induced by treatment with the composition for removing senescent cells according to the present invention significantly reduces the survival rate of senescent cells, thereby fundamentally blocking and suppressing the expression and secretion of various aging-related pathological factors secreted from senescent cells. Therefore, the composition for removing senescent cells according to the present invention can be usefully utilized for the improvement, treatment, or prevention of aging-related diseases and disorders. Furthermore, the composition for removing senescent cells according to the present invention can be usefully utilized in cosmetics, health functional foods, animal products, etc. in relation to aging-related diseases and disorders associated with senescent cells.
[0129] Hereinafter, the present invention will be described in detail, using examples and the like, to aid understanding. However, the examples according to the present invention may be modified in various different forms, and the scope of the present invention should not be construed as being limited to the following examples. The examples of the present invention are provided to more fully explain the present invention to those of average skill in the art.
[0130] The present inventors performed several evaluations using LX-112 (ethaselen, 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane) as an exemplary compound to evaluate the effect of senescent cell removal on the improvement, treatment, or prevention of senescent cell-related diseases and disorders. The results of these experiments are disclosed in WO2023-085787 A1, the entire contents of which are hereby incorporated by reference herein.
[0131] Example 11. Screening of various compounds that remove aged human cells through a mechanism different from that of existing senescent cell removal agents.
[0132] Based on the results of Example 10 of WO2023-085787 A1, unlike existing senescent cell removal agents such as ABT-263, a compound that induces death of senescent cells through a mechanism similar to LX-112 that induces death was screened based on HMGN1, etc. In the same manner as Example 1 of WO2023-085787 A1, cells treated with doxorubicin or a control group (DMSO) and cultured were treated with the test compound at a concentration of 30 μM (except for LX-305, LX-1302, LX-1603, LX-2005, LX-2702, LX-2901, and LX-3106 at 90 μM, and for LX-1103 and LX-2007 at 270 μM). The following test compounds were synthesized and purchased from Medchemexpress, Selleckchem, Cayman, Medkoo, Sigma, Molport, Enzo, TCI, Santa Cruz, REONSIMI, Abcam, Alfa Aesar, APExBIO, BOCSCI, Merck, Thermo Fisher Scientific, R&D Systems, ChemFaces, Aobious, etc. The amount of HMGN1 secreted into the cell culture medium was measured using an enzyme-linked immunosorbent assay (ELISA Kit, purchased from AssayGenie) in the same manner as in Example 10 of WO2023-085787 A1. In cells that were not induced to undergo senescence treated with the control group (DMSO), the amount of HMGN1 exceeding the effective level (sensitivity: 35 pg / ml) that could be analyzed under both untreated and treated conditions with the test compound was not measured. On the other hand, in cells that were induced to undergo senescence by treatment with doxorubicin, the amount of HMGN1 of 80 to 90 pg / ml was measured. This amount was calculated as 100%, and the amount of HMGN1 was measured under conditions in which aged cells were treated with the test compound, and the results are shown in the table below.
[0133]
[0134] As a result, the amount of HMGN1 secreted from senescent cells that died when treated with the test compound increased, similar to LX-112. In addition, as in the result obtained by treating LX-112 of Example 10 of WO2023-085787 A1, the caspase inhibitor did not effectively inhibit the death of senescent cells caused by the test compound, and even when the caspase inhibitor was present, the test compound was still able to induce and remove the death of senescent cells. From this, it was confirmed that the test compound induces the death of senescent cells through a mechanism different from that of ABT-263.
[0135] Furthermore, the degree of death of senescent cells analyzed based on the increase in the amount of HMGN1 was measured using the CellTiter-Glo Luminescent Cell Viability Assay (purchased from Promega) by treating cells in which senescence was induced by treating doxorubicin in the same manner as in Example 1 of WO2023-085787 A1, and treating the test compounds at designated concentrations. The cell viability results are shown in the table below.
[0136]
[0137] As a result, cell viability decreased rapidly as the concentration of the test compound increased in senescent cells. This reaffirmed the ability of the test compound of the present invention to effectively eliminate senescent cells by inducing their death.
[0138] In this way, while the cell viability decreased in senescent cells and the total cell number decreased rapidly, when the test compound was treated in cells that were not induced to senescence by treating the control group (DMSO), the total cell number continuously increased with growth. From this, it was reconfirmed that the test compound can selectively remove senescent cells, as in the result of LX-112 in Example 1-2 of WO2023-085787 A1. The property of killing and removing senescent cells is not simply related to the generation of reactive oxygen species (ROS) within the cells. This is because even when H2O2 (purchased from Deoksan Scientific), which has a strong oxidizing effect that increases reactive oxygen species within the cells, or NAC (N-acetyl cysteine, purchased from Sigma), which has a strong antioxidant effect that reduces reactive oxygen species, were treated at excessive concentrations (1 or 20 mM), senescent cells were hardly removed. Ultimately, it was confirmed that the test compound of the present invention eliminates senescent cells through a death mechanism different from apoptosis through a specific target.
[0139] Example 12. Removal of aged cancer cells by the compound of the present invention
[0140] A549 (purchased from ATCC), a lung adenocarcinoma cell line derived from humans, was cultured in a designated medium (RPMI-1640, purchased from GenDEPOT; 10% FBS, purchased from GenDEPOT; 100 U / ml Penicillin & Streptomycin, purchased from Invitrogen), and senescence was induced using the same method as in Example 1 of WO2023-085787 A1. The test compounds were treated at a concentration of 30 μM (except for LX-305, LX-905, LX-1302, LX-1601, LX-1603, LX-2003, LX-2702, LX-2901, and LX-3106 at 90 μM, and for LX-1103, LX-2005, and LX-2007 at 270 μM) to cells cultured with doxorubicin or a control (DMSO). The amount of HMGN1 secreted into the cell culture medium was measured using an enzyme-linked immunosorbent assay (ELISA Kit, purchased from AssayGenie) in the same manner as in Example 10 of WO2023-085787 A1. In non-senescent cancer cells treated with the control group (DMSO), no amount of HMGN1 exceeding the effective level for analysis was measured under both untreated and treated conditions with the test compound. On the other hand, in cancer cells senescent by doxorubicin treatment, the amount of HMGN1 measured under the untreated condition was calculated as 100%, and the amount of HMGN1 was measured under the treated condition of the senescent cancer cells, and the results are shown in the table below.
[0141]
[0142] As a result, the amount of HMGN1 secreted by senescent cancer cells that were killed when treated with the test compound increased. In addition, as in the result obtained by treating LX-112 of Example 10 of WO2023-085787 A1, the caspase inhibitor did not effectively inhibit the death of senescent cells by the test compound, and even when the caspase inhibitor was present, the test compound was still able to induce and remove the death of senescent cells. From this, it was confirmed that the test compound induces the death of senescent cancer cells through a mechanism different from that of ABT-263.
[0143] Furthermore, the degree of death of aged cancer cells analyzed based on the increase in HMGN1 was measured by treating aged cancer cells with doxorubicin in the same manner as in Example 1 of WO2023-085787 A1, treating the test compounds at designated concentrations, and measuring the cell viability using CellTiter-Glo Luminescent Cell Viability Assay (purchased from Promega). The cell viability results are shown in the table below.
[0144]
[0145] As a result, cell viability in senescent cancer cells decreased rapidly at higher concentrations of the test compound. This reaffirmed the ability of the test compound of the present invention to effectively eliminate senescent cancer cells by inducing their death.
[0146] Thus, while cell viability decreased in aged cancer cells, leading to a rapid decrease in the total cell population, when the test compound was applied to cancer cells treated with DMSO (a control group) and senescence was not induced, the total cell population continued to increase with growth. This reaffirmed the ability of the test compound to selectively eliminate aged cancer cells by inducing apoptosis.
[0147] Therefore, the compound of the present invention can be usefully utilized in prosenescence anti-cancer therapy, which induces senescence in cancer cells and subsequently removes the aged cancer cells. In other words, the compound of the present invention can be used for the treatment or prevention of proliferative diseases such as cancer.
[0148] Example 13. Removal of aged human cells by secretion of cells treated with the compound of the present invention.
[0149] WO2023-085787 A1 In the same manner as in Example 1, foreskin cells treated with doxorubicin or the control group (DMSO) and induced senescence were treated with LX-401 or LX-405 at a concentration of 30 μM, and cell viability was measured after 3 days using CellTiter-Glo Luminescent Cell Viability Assay (Promega) or an optical microscope. As a result of the measurement, it was confirmed that treatment with a high concentration of the test compound induced the death of almost all cells in both normally dividing (Proliferating) and senescent (Senescent) cells.
[0150] In this way, after treating the test compound at a high concentration that induced almost all cell death in both non-senescent and senescent cells, the test compound was removed by washing with PBS three times at a time point when the compound had entered the cells but cell death had not yet been induced (immediately after compound treatment, about 1 to 3 hours), and the medium was replaced with fresh medium and incubated for an additional 3 hours or more. During this additional incubation, the medium supernatant containing secretions from normally dividing (proliferating) and senescent (senescent) cells in which cell death had been induced was obtained by confirming using an optical microscope, etc. The obtained medium supernatant was replaced with the medium from normally dividing (proliferating) and senescent (senescent) cells, respectively, and the cell viability was measured after 3 days. The results are shown in the table below.
[0151]
[0152] As a result, both the supernatants obtained from proliferating and senescent cells in which cell death was induced by the test compound selectively induced cell death in senescent cells. However, neither of the two media induced cell death in proliferating cells. Thus, both the supernatants obtained from proliferating and senescent cells in which cell death was induced by LX-112 selectively induced cell death in senescent cells.
[0153] In addition, the supernatant obtained through the same process from the medium treated with the test compound without culturing cells (No Cells) did not induce the death of both normally dividing (Proliferating) and senescent cells. From this, it was confirmed that the supernatant containing substances secreted from cells treated with the test compound and induced to die can effectively remove senescent cells by inducing the death of senescent cells.
[0154] Furthermore, in Example 11, other test compounds were treated at high concentrations of 30 μM, 90 μM, and 270 μM in the same manner as described above, and cultured medium supernatants containing secretions from death-induced senescent cells were obtained to measure the degree of death of the senescent cells. The cell viability results are shown in the table below.
[0155]
[0156] As a result, it was reconfirmed that the supernatant containing secretions from cells induced to die by treatment with the test compound can effectively remove senescent cells by inducing their death. The same results were also confirmed with LX-112.
[0157] Example 14. Removal of aged cancer cells by secretion of cells treated with the compound of the present invention.
[0158] In the same manner as in Examples 12 and 13, senescence was induced by treating doxorubicin or the control (DMSO) and cultured cancer (A549) cells. LX-405 was treated at a concentration of 30 μM, and cell viability was measured after 3 days using CellTiter-Glo Luminescent Cell Viability Assay (Promega) or an optical microscope. Supernatants containing secretions from normally dividing (proliferating) and senescent (senescent) cancer cells were obtained in the same manner as in Example 13, and treated to normally dividing (proliferating) and senescent (senescent) cancer cells. Thereafter, cell viability was measured, and the results are shown in the table below.
[0159]
[0160] As a result, it was confirmed that the supernatant containing secretions from cancer cells induced to die by treatment with the test compound could more effectively remove aged cancer cells compared to normally dividing cancer cells.
[0161] Furthermore, in Example 12, the supernatant from death-induced cells was obtained by treating other test compounds at high concentrations of 30 μM, 90 μM, and 270 μM in the same manner as described above, and the degree of death of the aged cancer cells was measured. As a result, it was confirmed that the aged cancer cells could be effectively removed, as in the experimental results of Example 12.
[0162] Example 15. Removal of senescent cells and related senescence inhibition activity by the compound of the present invention in aged mice
[0163] WO2023-085787 A1 In the same manner as Example 7-1, LX-405 (5% DMSO in PBS solution, 10 mg / kg, intraperitoneal administration), LX-801 (PBS, 100 mg / kg, intraperitoneal administration), LX-1102 (0.5% CMC-Na solution, 100 mg / kg, oral administration), LX-1801 (PBS, 50 mg / kg, intraperitoneal administration), LX-2101 (0.5% CMC-Na solution, 10 mg / kg, intraperitoneal administration), and LX-3403 (mouse anti-PD-1 antibody (purchased from BioXcell), 100 μg, intraperitoneal administration) were administered to naturally aged mice under the designated conditions for 5 days. The control group was administered only the solution in the same volume. After the end of drug administration, the method described in each example below was performed. WO2023-085787 A1 In the same manner as in Examples 7-2 and 7-6, mice were sacrificed, and total RNA was extracted from liver tissue, and qRT-PCR was performed and analyzed using the synthesized cDNA. The table below shows the results of the mRNA amounts of p16, a senescence-related marker, and MMP3 and IL6, senescence-associated secretory factors (SASPs), in mice that were not treated with the test compound and in which natural aging was induced. The mRNA amounts of p16, MMP3, and IL6 after natural aging was induced were each calculated as 100%, and compared with the mRNA amounts of p16, MMP3, and IL6 after treatment with the test compound. Furthermore, an activity evaluation (open field test) was performed in order to analyze senescence due to aging in mice in the same manner as in WO2023-085787 A1 Example 7-7. The table below quantitatively represents the activity assessment, a criterion for senescence, in mice that underwent natural aging, under untreated and treated conditions with the test compound. The amount of activity assessed after aging was calculated as 100% and compared with the amount assessed after treatment with the test compound.
[0164]
[0165] As a result, as shown in the experimental results of Examples 7-2, 7-6, and 7-5 of WO2023-085787 A1, when mice aged naturally, the amounts of p16, MMP3, and IL6 in the liver tissue increased, but when the test compound was treated, the mRNA amounts of p16, MMP3, and IL6 decreased. From this, it was confirmed that the test compound effectively reduces the amounts of p16, a senescence-related marker, and MMP3 and IL6, senescence-associated secretory factors (SASPs), by eliminating senescent cells that increase in mice due to natural aging.
[0166] Furthermore, as shown in the experimental results of WO2023-085787 A1 Example 7-7, when mice naturally aged, their activity decreased, but when treated with the test compound, activity increased. From this, it was confirmed that the test compound improved aging in mice by eliminating senescent cells that increase with aging.
[0167] Example 16. Removal of senescent cells and related senescence inhibition activity by killing senescent cells by the compound of the present invention in aging mice
[0168] To obtain preadipocytes, inguinal adipose tissue was collected from 8-week-old female C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center). The adipose tissue was cut into small pieces and treated with collagenase to break down the adipose tissue. Then, centrifugation was performed to collect the stromal vascular fraction (SVF) containing preadipocytes. The SVF was washed with washing medium (HBSS, purchased from GenDEPOT; 3.5% Albumin Fraction V, purchased from GenDEPOT; 100 U / ml Penicillin & Streptomycin, purchased from Invitrogen), mixed again, and filtered through a 100 μm nylon mesh for extraction. The separated preadipocytes were cultured in a designated medium (DMEM, purchased from GenDEPOT; 20% FBS, purchased from GenDEPOT; 100 U / ml Penicillin & Streptomycin, purchased from Invitrogen). WO2023-085787 A1 In the same manner as Example 1, doxorubicin was treated at a concentration of 250 nM for 24 hours, and further cultured for 21 days to induce cell senescence. In the same manner as Example 13, the preadipocytes were treated with the test compound, and it was confirmed by an optical microscope that most of the senescent cells were killed. After washing with PBS (purchased from Welgene), 5X10 5cells / 200 μl concentration in PBS and administered subcutaneously to 8-week-old female C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center). 7 and 10 days after administration of the killed senescent cells, 2 million aged preadipocytes were mixed in 200 μl of PBS and administered intraperitoneally to the mice. After administration of the killed senescent cells, obesity was induced in the mice with a high-fat diet (DIO) for 8 weeks in the same manner as in Example 9-1 of WO2023-085787 A1. After that, the mice were sacrificed in the same manner as in Example 7-2 of WO2023-085787 A1, and total RNA was extracted from the inguinal fat tissue, and qRT-PCR was performed and analyzed using the synthesized cDNA. The table below shows the results of showing the mRNA amounts of p16, a senescence-associated marker, and MMP3 and IL6, senescence-associated secretory factors (SASPs), under conditions in which cells were not administered and were administered apoptosis-induced by the test compound. The mRNA amounts of p16, MMP3, and IL6 in senescent cells not administered and were calculated as 100% were compared with the mRNA amounts of p16, MMP3, and IL6 after administration of senescent cells induced to die by the test compound. Furthermore, an activity evaluation (open field test) was performed to analyze senescence due to aging in mice using the same method as WO2023-085787 A1 Example 7-7. The table below shows the results of quantitatively showing the activity, which is a criterion for judging senescence, under conditions in which senescent cells induced to die by the test compound were not administered and were administered. The amount of activity evaluated without administering senescent cells induced to die by the test compound was calculated as 100%, and compared with the amount of activity evaluated after administering senescent cells induced to die by the test compound.
[0169]
[0170] As a result, as shown in the experimental results of Examples 9-2 and 9-3 of WO2023-085787 A1, when mice were aged due to obesity, the amounts of p16, MMP3, and IL6 increased in adipose tissues, etc., but in comparison, when senescent cells induced to die by the test compound were administered to mice and aging was induced due to obesity, the mRNA amounts of p16, MMP3, and IL6 decreased. From this, it was confirmed that when senescent cells induced to die by the test compound were administered to mice, senescent cells that increase in mice due to aging such as obesity were eliminated, thereby effectively reducing the amounts of p16, which is an aging-related marker, and MMP3 and IL6, which are senescence-associated secretory factors (SASPs).
[0171] Furthermore, as shown in the experimental results of Example 9-4 of WO2023-085787 A1, when mice aged due to obesity, their activity decreased. However, in comparison, when senescent cells induced to die by the test compound were administered to the mice and aging was induced, their activity increased. From this, it was confirmed that when senescent cells induced to die by the test compound were administered to the mice, senescent cells that increase in the mice due to aging, such as obesity, were eliminated, thereby improving the aging of the mice.
[0172] Thus, the effect of administering senescent cells induced to die by the test compound, which improves senescence by eliminating senescent cells and reducing p16 and senescence-associated secretory factor (SASP), was not observed in C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) with a Rag-2 gene knockout. Therefore, it was confirmed that the effect of eliminating and reducing senescent cells by using senescent cells induced to die by the test compound is related to the immune system in vivo. Ultimately, the combined administration of immune checkpoint inhibitors, cytokines (interferons, interleukins, etc.), and polysaccharide-K, which are known to contribute to this immune response process in vivo, can further increase the effect of eliminating senescent cells. In this way, when HMGN1, which binds to the Toll-like receptor, is administered together with an immune checkpoint inhibitor, cytokine, etc., the immune response can be synergistically activated. In this regard, in the experiment of Example 16, when LX-3403, a mouse anti-PD-1 (purchased from BioXcell), was administered intraperitoneally twice a week at a concentration of 100 μg for 8 weeks 7 days after administration to senescent cells induced to die by a test compound such as LX-405, the amount of p16 mRNA was further reduced by approximately 27%. From this, it was confirmed that senescent cells induced to die by a test compound can effectively remove senescent cells that increase in mice in which aging is induced alone or in combination with an immune response activator.Through such in vivo verification, it is also possible to induce the removal of senescent cells by reacting them with immune cells (dendritic cells, lymphocytes, macrophages, monocytes, neutrophils, epithelial cells, innate lymphoid cells, mast cells, eosinophils, basophils, natural killer cells, etc.) or immune tissues in vitro.
[0173] Example 17. Screening of various compounds that remove aged human cells through a mechanism different from that of existing senescent cell removal agents.
[0174] In the same manner as Example 11, compounds that induce death of senescent cells through a mechanism similar to LX-112 (ethaselen (1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]ethane)) were screened based on HMGN1, etc. In the same manner as Example 1 of WO2023-085787 A1, cells treated with doxorubicin and cultured were treated with the test compounds at a concentration of 30 μM (except for LX-5211, LX-5433, LX-6530, LX-9105, LX-9118, LX-9321, and LX-9602, which were 90 μM, and LX-9336, which were 2.4 mM). The following test compounds were synthesized and purchased from Medchemexpress, Selleckchem, Cayman, Medkoo, TCI, Probechem, REONSIMI, etc. and used. The amount of HMGN1 secreted into the cell culture medium was measured using an enzyme-linked immunosorbent assay (ELISA Kit, purchased from AssayGenie) in the same manner as in Example 11. In cells that were not induced to undergo senescence and treated with the control group (DMSO), no amount of HMGN1 exceeding the effective level (sensitivity: 35 pg / ml) for analysis was measured under both the untreated and treated conditions with the test compound. On the other hand, in cells that were induced to undergo senescence by treatment with doxorubicin, an amount of HMGN1 of 80 to 90 pg / ml was measured. This amount was calculated as 100%, and the amount of HMGN1 was measured under the condition of treating the test compound in senescent cells, and the results are shown in the table below.
[0175]
[0176] As a result, the amount of HMGN1 secreted from senescent cells that died when treated with the test compound increased, similar to LX-112. In addition, as in the result obtained by treating LX-112 of Example 10 of WO2023-085787 A1, the caspase inhibitor did not effectively inhibit the death of senescent cells caused by the test compound, and even when the caspase inhibitor was present, the test compound was still able to induce and remove the death of senescent cells. From this, it was confirmed that the test compound induces the death of senescent cells through a mechanism different from that of ABT-263.
[0177] Furthermore, the degree of death of senescent cells analyzed based on the increase in the amount of HMGN1 was evaluated using the same method as Example 1 of WO2023-085787 A1. Test compounds were treated at designated concentrations to cells induced to senescence by doxorubicin treatment, and the cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (purchased from Promega). The cell viability results are shown in the table below.
[0178]
[0179]
[0180] As a result, cell viability decreased rapidly as the concentration of the test compound increased in senescent cells. This reaffirmed the ability of the test compound of the present invention to effectively eliminate senescent cells by inducing their death.
[0181] In this way, while cell viability decreased in senescent cells and the total number of cells decreased rapidly, when the test compound was treated in cells that were not induced to undergo senescence by treating the control group (DMSO), the total number of cells continuously increased with growth. From this, it was reconfirmed that the test compound can selectively eliminate senescent cells, similar to the results of LX-112 in Example 1-2 of WO2023-085787 A1.
[0182] Example 18. Removal of aged cancer cells by the compound of the present invention
[0183] A549 (purchased from ATCC), a lung adenocarcinoma cell line derived from humans, was cultured in a designated medium (RPMI-1640, purchased from GenDEPOT; 10% FBS, purchased from GenDEPOT; 100 U / ml Penicillin & Streptomycin, purchased from Invitrogen), and senescence was induced using the same method as in Example 1 of WO2023-085787 A1. The test compounds were treated at a concentration of 30 μM (except for LX-5211, LX-5433, LX-6530, LX-6800, LX-9105, LX-9118, LX-9131, LX-9136, LX-9302, LX-9321, Lx-9565, and LX-9602 at 90 μM, and LX-9336 at 2.4 mM) in cells treated with doxorubicin. The amount of HMGN1 secreted into the cell culture medium was measured using an enzyme-linked immunosorbent assay (ELISA Kit, purchased from AssayGenie) in the same manner as in Example 10 of WO2023-085787 A1. In non-senescent cancer cells treated with the control group (DMSO) as in Example 11, no amount of HMGN1 exceeding the analyzable value was measured under both untreated and treated conditions with the test compound. On the other hand, in cancer cells treated with doxorubicin, where senescence was induced, the amount of HMGN1 measured under conditions where the test compound was not treated was calculated as 100%, and the amount of HMGN1 was measured under conditions where the test compound was treated in the senescent cancer cells. The results are shown in the table below.
[0184]
[0185] As a result, the amount of HMGN1 secreted from the senescent cancer cells that were killed when treated with the test compound increased. In addition, as in the result obtained by treating LX-112 of Example 10 of WO2023-085787 A1, the caspase inhibitor did not effectively inhibit the death of senescent cells by the test compound. In contrast, even when the caspase inhibitor was present, the test compound was still able to induce and eliminate the death of senescent cells. From this, it was confirmed that the test compound induces the death of senescent cancer cells through a mechanism different from that of ABT-263.
[0186] Furthermore, the degree of death of aged cancer cells analyzed based on the increase in HMGN1 was evaluated using the same method as WO2023-085787 A1 Example 1. Cancer cells induced to become aged by treatment with doxorubicin were treated with test compounds at designated concentrations, and cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay (purchased from Promega). The measurement results are shown in the table below.
[0187]
[0188]
[0189] As a result, cell viability in senescent cancer cells decreased rapidly at higher concentrations of the test compound. This reaffirmed the ability of the test compound of the present invention to effectively eliminate senescent cancer cells by inducing their death.
[0190] Thus, while cell viability decreased in aged cancer cells, leading to a rapid decrease in the total cell population, when the test compound was applied to cancer cells treated with DMSO (a control group) and senescence was not induced, the total cell population continued to increase with growth. This reaffirmed the ability of the test compound to selectively eliminate aged cancer cells by inducing apoptosis.
[0191] Therefore, the compound of the present invention can be usefully utilized in prosenescence anti-cancer therapy, which induces senescence in cancer cells and subsequently removes the aged cancer cells. In other words, the compound of the present invention can be used for the treatment or prevention of proliferative diseases such as cancer.
[0192] Example 19. Suppression and improvement of aged tumors
[0193] Seven-week-old male BALB / c nude mice (purchased from KRIBB Laboratory Animal Resource Center) were allowed to adapt to the experimental environment for one week, and then randomly assigned to experimental and control groups. The mice were evaluated using the same method as in Example 2-1 of WO2023-085787 A1. The cultured human osteosarcoma cell line SAOS-2 (10 6 (dog cells) were mixed in PBS and then administered subcutaneously to anesthetized mice using 2% isoflurane (purchased from Sigma). Tumors were sized 50 mm 2 When the tumor size was measured, doxorubicin was mixed in a 1:1 solution of distilled water and PBS (pH 7.2) at a concentration of 10 mg / kg and administered intraperitoneally to induce tumor senescence. After 10 days, LX-5701 mixed in PBS at a concentration of 360 mg / kg was administered orally daily for 21 days, or LX-2101 mixed in PBS solution with 5% DMSO (purchased from Sigma) at a concentration of 20 mg / kg or LX-2102 mixed in PBS solution with 5% DMSO at a concentration of 10 mg / kg was administered intraperitoneally daily for 21 days, and then the tumor size was measured. The control group was repeatedly administered a solution mixed with doxorubicin and then the tumor size was measured. The measurement results are compared and shown in the table below.
[0194]
[0195] As a result, as shown in the table above, when LX-5701, LX-2101, or LX-2102 was treated (DOX→LX) in tumors that induced senescence in mice, the tumor size was more effectively suppressed and reduced than when doxorubicin was repeatedly treated (DOX→DOX). From this, it was confirmed that when the formed tumor was treated with the test compound, which is a component for inducing senescence and removing senescent cells, a more effective anticancer effect was exhibited than when the mice were repeatedly treated with anticancer drugs as chemotherapy.
[0196] Furthermore, when each of the test compounds of this example in Table 16 was administered together with LX-6806 (purchased from MedChemExpress) (5% DMSO + 95% corn oil, 30 mg / kg, intraperitoneal administration), LX-6807, LX-9118 (purchased from MedChemExpress) (PBS, 200 mg / kg, oral administration), LX-9423 (purchased from MedChemExpress) (PBS, 10 mg / kg, oral administration), LX-9744 (purchased from MedChemExpress) (PBS, 60 mg / kg, intraperitoneal administration), or LX-3403 (anti-PD-1 antibody, purchased from BioXcell) (PBS, 10 mg / kg, intraperitoneal administration), the CI (combination index) was 0.62 to 0.83, indicating synergy in efficacy. Similar synergistic results were confirmed when LX-8401 (anti-PD-L1 antibody, purchased from BioXcell) (PBS, 10 mg / kg, intraperitoneal administration) was administered instead of LX-3403, and LX-9422 (purchased from MedChemExpress) (PBS, 20 mg / kg, oral administration) was administered instead of LX-9423.
[0197] Example 20. Improvement of fibrosis
[0198] WO2023-085787 A1 The anti-fibrotic activity of LX-5701 was confirmed using the same method as Example 6-2. The thickness of the peritoneal mesothelial cell layer was quantitatively evaluated in mice with peritoneal fibrosis induced by chlorhexidine gluconate (CHG) under conditions in which LX-5701 was not treated and was treated. The results are shown in the table below.
[0199]
[0200] As a result, as shown in the table above, chlorhexidine gluconate increased the thickness of the peritoneum, and LX-5701 suppressed and reduced the increased thickness. From this, it was confirmed that LX-5701 effectively suppresses and treats fibrosis.
[0201] Furthermore, when LX-5701, the test compound of this example, was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.51 to 0.81, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0202] Example 21. Removal of senescent cells and associated anti-aging activity in naturally induced aging mice.
[0203] Example 21-1. Establishment of a naturally induced aging mouse model
[0204] 22-month-old female C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) were allowed to adapt to the experimental environment for one week, and then aged mice were randomly assigned to the experimental and control groups. 8-week-old non-aged mice served as the control group. LX-403 was mixed with a 10% ethanol solution of PEG400 and administered orally at a concentration of 25 mg / kg daily for 21 days or administered to the skin, joints, or eyes at a concentration of 1 μM. LX-1801 was mixed with distilled water containing 4% DMSO, 30% PEG300, and 5% Tween80 and administered to the skin, joints, or eyes at a concentration of 0.4 μM daily for 21 days. LX-2001 was mixed with PBS and administered to the skin, joints, or eyes at a concentration of 2 μM daily for 21 days. LX-2002 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered to the skin, joints, or eyes at a concentration of 2 μM daily for 21 days. LX-2003 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered to the skin, joints, or eyes at a concentration of 10 μM daily for 21 days. LX-2005 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered to the skin, joints, or eyes at a concentration of 90 μM daily for 21 days. LX-2007 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered to the skin, joints, or eyes at a concentration of 90 μM daily for 21 days. LX-2707 was mixed with corn oil and administered orally at a concentration of 600 mg / kg daily for 21 days. LX-3001 was mixed with PBS and administered orally at a concentration of 300 mg / kg daily for 21 days. LX-3002 was mixed with distilled water containing 4% DMSO, 30% PEG300, and 5% tween80 and administered orally at a concentration of 10 mg / kg daily for 21 days.LX-5401 was mixed in 5% PBS and administered intraperitoneally at a concentration of 50 mg / kg daily for 21 days or administered to the skin, joints, or eyes at a concentration of 10 μM. LX-5411 was mixed in 5% PBS and administered orally at a concentration of 10 mg / kg daily for 21 days or administered to the skin, joints, or eyes at a concentration of 3 μM. LX-5701 was mixed in PBS and administered orally at a concentration of 360 mg / kg daily for 21 days. LX-6807 was mixed in saline and administered intraperitoneally at a concentration of 1 mg / kg daily for 21 days. LX-2101 or LX-2102 was mixed in 5% DMSO in PBS and administered intraperitoneally at a concentration of 20 mg / kg or 10 mg / kg, respectively, daily for 21 days. The control group received only the solution in the same volume. After the end of drug administration, the methods described in each example below were performed.
[0205] Example 21-2. Reduction in the amount of aging-related markers (p16)
[0206] Mice were sacrificed, and RNA was extracted from each organ tissue using the same method as in Example 7-2 of WO2023-085787 A1. The synthesized cDNA was used for qRT-PCR. The table below shows the mRNA levels of p16, a senescence-related marker, under conditions in which senescence was induced and no test compound treatment was performed and treated. The mRNA level of p16 after senescence induction was calculated as 100% and compared with the mRNA level of p16 after test compound treatment.
[0207]
[0208] As shown in the table above, treatment of mice with aging-induced senescence with the test compound resulted in a decrease in the amount of p16 mRNA in various organ tissues. This confirms that the test compound effectively reduces the amount of p16, an aging-related marker that increases in various organ tissues of mice, by eliminating senescent cells that increase with aging.
[0209] Example 21-3. Reduction in the amount of aging-related marker (SA-β-gal)
[0210] Mice were sacrificed, tissue sections were prepared from organ tissues of each site, and stained for a senescence-associated marker (SA-β-gal) using the same method as WO2023-085787 A1 Example 7-3. The table below shows the staining area of the senescence-associated marker SA-β-gal under conditions in which senescence was induced and the test compound was not treated and treated.
[0211]
[0212] As a result, as shown in the table above, when the test compound was treated in mice with aging, the staining area of SA-β-gal decreased in various organ tissues. From this, it was confirmed that the test compound effectively reduces the amount of SA-β-gal, an aging-related marker that increases in various organ tissues of mice, by eliminating senescent cells that increase with aging.
[0213] Example 21-4. Reduction in the amount of age-related degenerative markers (lipofuscin)
[0214] Mice were sacrificed and evaluated using the same method as WO2023-085787 A1 Example 7-4. Muscle tissue sections were stained with Sudan Black B (purchased from Sigma) to analyze the amount of lipofuscin, a marker of aging-related degeneration. The table below shows the stained area of lipofuscin, a marker of aging-related degeneration, under conditions in which aging was induced and test compounds were not treated and treated.
[0215]
[0216] As shown in the table above, treatment of mice with aging-induced disease with the test compound resulted in a decrease in the staining area for lipofuscin in various tissues. This confirms that the test compound effectively reduces the amount of lipofuscin, a marker of age-related degeneration that increases in mouse muscle tissue, by eliminating senescent cells that increase with age.
[0217] Example 21-5. Reduction in the amount of senescence-associated secretory factor (SASP)
[0218] The levels of IL6 and MCP1, which are senescence-associated secretory factors (SASPs), were measured in serum collected from mice using an enzyme-linked immunosorbent assay (ELISA Kit, purchased from R&D Systems). The table below shows the levels of IL6 and MCP1, which are senescence-induced SASPs, under untreated and treated conditions with the test compound.
[0219]
[0220] As a result, as shown in the table above, treatment of mice with aging-induced senescence with the test compound resulted in a decrease in the levels of IL6 and MCP1 in the serum. This confirms that the test compound effectively reduces the levels of IL6 and MCP1, senescence-associated secretory factors (SASPs) that increase in the serum of mice, by eliminating senescent cells that increase with aging.
[0221] Example 21-6. Reduction in the amount of senescence-associated secretory factor (SASP)
[0222] WO2023-085787 A1 Using cDNA synthesized in the same manner as Example 7-2, qRT-PCR was performed and analyzed for the senescence-associated secretory factors (SASPs), MMP3, IL1β, MMP12, IL6, and MMP13. The table below shows the mRNA amounts of the senescence-associated secretory factors (SASPs), MMP3, IL1β, MMP12, IL6, and MMP13, under conditions in which senescence was induced and no test compound treatment and treatment were performed. The mRNA amount of each factor after senescence induction was calculated as 100% and compared with the mRNA amount of each factor after test compound treatment.
[0223]
[0224] As a result, as shown in the table above, when the test compound was treated in mice with induced aging, the mRNA amount of each senescence-associated secretory factor (SASP) decreased in various organ tissues. From this, it was confirmed that the test compound effectively reduced the amount of senescence-associated secretory factors (SASPs), such as MMP3, IL1β, MMP12, IL6, and MMP13, which increase in various organ tissues of the mouse, by eliminating senescent cells that increase with aging.
[0225] Example 21-7. Improvement of frailty (decrease in activity, endurance, muscle strength and grip strength, sarcopenia, muscular dystrophy, lipoatrophy, etc.)
[0226] To analyze frailty due to aging in mice, an activity evaluation (open field test), an endurance evaluation (wire hanging test), and a muscle and grip strength evaluation (grip strength test) were performed using the same method as WO2023-085787 A1 Example 7-7. The table below shows the results quantitatively showing the criteria for aging, such as activity, endurance, muscle strength, and grip strength, under conditions in which aging was induced and the test compound was not treated and treated. The amount of each evaluation after aging was induced was calculated as 100% and compared with the amount of each evaluation after treatment with the drug according to the present invention.
[0227]
[0228] As shown in the table above, treatment of aged mice with the test compound resulted in increased activity, endurance, muscle strength, and grip strength. Furthermore, treatment with the test compound also reduced levels of p16, a marker of aging, lipofuscin, a marker of aging-related degeneration, and IL6, a senescence-associated secretory factor (SASP), in muscle tissue. This confirms that the test compound alleviates aging in mice by eliminating senescent cells, which increase with age.
[0229] As a fact consistent with this improvement effect, it was confirmed from the results in the above table that the test compound increased the amount of muscle tissue of the quadriceps and gastrocnemius of aged mice and inguinal fat and epididymal fat tissue, and improved sarcopenia, muscular atrophy, and lipoatrophy.
[0230] Furthermore, when each of the test compounds of the present example in Table 23 was administered together with LX-6806, LX-6807 (in Table 23, cases where LX-6807 was administered were excluded because it was not combination administration due to duplicate administration of the same LX-6807. The same applies to all examples in which LX-6807 was used as the second active ingredient), LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.69 to 0.82, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403 and LX-9422 was administered instead of LX-9423.
[0231] Example 21-8. Improvement of geriatric depression and anxiety
[0232] Depression and anxiety are among the primary characteristics of old age. Recent analyses have shown that effectively reducing the amount of age-associated secretory factor (SASP) by eliminating senescent cells can treat and improve symptoms of geriatric depression and anxiety. Geriatric depression occurs alongside symptoms of chronic fatigue syndrome (fatigue, pain, and cognitive decline).
[0233] In Examples 21-5 and 21-6, the amount of senescence-associated secretory factor (SASP) in serum and each tissue collected from mice was reduced by treatment with LX-5701, LX-2101, or LX-2102. It was confirmed that geriatric depression and anxiety symptoms can be improved by eliminating senescent cells that increase with aging in mice and effectively reducing the amount of senescence-associated secretory factor (SASP).
[0234] In addition, when LX-401, LX-405, LX-2101, LX-2707, LX-3001, LX-3002, LX-3403, LX-5401, LX-5411, LX-5701, LX-6806, LX-6807, LX-9118, LX-9423, or LX-9744 was treated in mice in which senescence was induced, it was confirmed that senescent cells were eliminated at a similar level, and the amount of senescence-associated secretory factor (SASP) was reduced along with senescence-associated markers p16, SA-β-gal, and lipofuscin, and symptoms of geriatric depression and anxiety were improved.
[0235] Example 21-9. Improvement of kidney damage and diseases (chronic kidney disease, glomerulosclerosis, nephropathy, renal failure, etc.)
[0236] The amounts of urea and creatinine, which are markers of kidney damage, in serum collected from mice were measured by spectrophotometry using kits (purchased from BioAssay Systems and Sigma). In addition, the amount of Agtr1a mRNA, a marker of kidney damage, was measured by qRT-PCR as described in WO2023-085787 A1 Example 7-2. The table below shows the results quantitatively showing the amounts of urea, creatinine, and Agtr1a mRNA, which are markers of kidney damage, under conditions in which aging was induced and the test compound was not treated and treated. The amount of each factor after aging was induced was calculated as 100% and compared with the amount of each factor after treatment with the test compound.
[0237]
[0238] As a result, as shown in the table above, treatment of aged mice with the test compound resulted in decreased levels of urea, creatinine, and Agtr1a mRNA. This confirms that the test compound improves renal damage and diseases in mice, such as chronic kidney disease, glomerulosclerosis, nephropathy, and renal failure, by eliminating senescent cells that increase with aging.
[0239] Furthermore, when each of the test compounds of this example in Table 24 was administered together with LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.53 to 0.74, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0240] In addition, the efficiency of kidney transplantation according to the removal of senescent cells in the kidney was evaluated. Kidneys extracted from aged mice of Example 21-1, untreated and treated with LX-403, were transplanted into young 3-month-old mice, and the efficiency of kidney transplantation was evaluated 3 days later through analysis of aging and kidney damage markers. As a result, when treated with LX-403, the amount of p16, an aging-related marker, and serum urea and creatinine, markers of kidney damage, decreased in the kidney after transplantation compared to the control group. From this, it was confirmed that LX-403 improves the efficiency of long-term kidney transplantation by removing senescent cells that increase in the kidney with mouse aging. This improvement in transplantation efficiency was also confirmed when kidneys extracted from aged mice were transplanted after removing senescent cells under ex vivo conditions, such as by culturing them in an LX-403-containing medium. Furthermore, similar results of improved transplantation efficiency were confirmed when LX-401, LX-405, LX-5401, or LX-5411, which are similar to LX-403, were treated.
[0241] In addition, the efficiency of liver transplantation was evaluated. Livers extracted from aged mice of Example 21-1, untreated and treated with LX-403, were transplanted into young 3-month-old mice, and the efficiency of liver transplantation was evaluated 3 days later through analysis of aging and liver damage markers. As a result, when treated with LX-403, the amount of p16, an aging-related marker of the liver after transplantation, and serum AST and ALT, liver damage markers, decreased compared to the control group. From this, it was confirmed that LX-403 improves the efficiency of long-term liver transplantation by removing senescent cells that increase in the liver with mouse aging. This improvement in transplantation efficiency was also confirmed when the livers extracted from aged mice were transplanted after removing senescent cells under ex vivo conditions, such as by culturing them in an LX-403-containing medium. Furthermore, similar results of improved transplantation efficiency were confirmed when LX-401, LX-405, LX-5401, or LX-5411, which are similar to LX-403, were treated.
[0242] In this way, it was confirmed that the transplantation efficiency was improved by removing senescent cells in the transplantation of foreign substances including various tissues and cells. When each of the test compounds of this example in Table 24 was administered, the CI (combination index) was 0.61 to 0.83 when LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403 was administered together, confirming that there was synergy in efficacy. Similar synergistic results were confirmed when LX-8401 was administered instead of LX-3403 and LX-9422 was administered instead of LX-9423.
[0243] Example 21-10. Improvement of skin aging
[0244] Frozen sections of skin tissue were stained with Hematoxylin / Eosin (H / E), and the thickness of the dermis was observed under an optical microscope. In addition, the mRNA amounts of collagen (COL1A1), a skin component, and SDF1, which suppresses pigmentation due to aging, were measured by qRT-PCR as described in WO2023-085787 A1 Example 7-2. The table below quantitatively shows the degree of skin aging according to dermal thickness and collagen (COL1A1) and SDF1 mRNA amounts in mice that were not treated with the test compound and under conditions in which natural aging was induced. In addition, biweekly examinations were performed for the onset of hair loss due to aging.
[0245]
[0246] As a result, as shown in the table above, when the test compound was treated in mice in which aging was induced, the thickness of the skin, the amount of collagen and SDF1 increased, and the area of hair loss decreased. In addition, p16 and SA-β-gal, which are aging-related markers in the skin tissue, and MMP1, MMP12, and MMP13, which are aging-related secretory factors (SASPs) and collagen-degrading enzymes, were also reduced by the test compound treatment. From this, it was confirmed that the test compound improved skin aging and diseases of the mouse, such as epidermal atrophy, loss of elasticity, wrinkles, hyperpigmentation, and hair loss, by removing senescent cells that increase with aging of the mouse. Furthermore, similar improvement results were confirmed when LX-401 or LX-405, which are similar to LX-403, LX-5401, or LX-5411, were treated.
[0247] Furthermore, when each of the test compounds of this example in Table 25 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.52 to 0.77, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0248] Example 21-11. Improved wound / damage healing ability
[0249] Various stresses and stimuli in various tissues cause various damages through the release of senescent-associated secretory factors (SASPs) from senescent cells. For example, senescent cells accumulated in the skin after laser, filler, botox, and thread-based skin boosters and lifting procedures, tattoos, plastic and cosmetic procedures, and surgery, as well as exposure to ultraviolet rays, burns, or other toxic substances, can delay wound healing and cause damage such as scars.
[0250] To assess the wound healing capacity of aged mice, two wounds of equal size were created on the dorsal skin using a 6 mm punch, and the wound sizes were measured using calipers. The table below shows the extent of wound healing in naturally aged mice after 7 days in untreated and treated conditions with the test compound.
[0251]
[0252] As a result, as shown in the table above, when the test compound was treated in mice in which aging was induced, the healing rate of skin wounds increased. In addition, in the skin tissue, aging-related markers such as p16, SA-β-gal, and lipofuscin, as well as aging-related secretory factors (SASPs) and collagen-degrading enzymes such as MMP1, MMP12, and MMP13 were also reduced. From this, it was confirmed that the test compound improved the wound healing ability of mice by eliminating senescent cells that increase with aging. Furthermore, similar improvement results were confirmed when LX-401 or LX-405, which are similar to LX-403, LX-5401, or LX-5411, were treated.
[0253] Furthermore, when each of the test compounds of this example in Table 26 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.69 to 0.78, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403 and LX-9422 was administered instead of LX-9423.
[0254] In addition, in order to evaluate the scar healing ability according to the wound, three wounds of the same size were created on the ears of rabbits using an 8 mm punch, and scar formation was induced through natural healing for four weeks. After confirming the formation of scars, the test compound of this example was administered intra-scar three times a week for four weeks to treat them, and the degree of scar healing was evaluated through visual evaluation. As a result, when the test compound of this example was treated on the scar area, the size of the scar was reduced compared to the control group, and the expression of collagen, a fibrosis marker, was also reduced. From this, it was confirmed that the test compound of this example improves scar-related skin diseases by removing senescent cells that increase in the scar area.
[0255] In this way, as in this example, by treating the test compounds of this example in Table 26 on areas of treatment and surgery using laser, filler, botox, thread, ultraviolet rays, and burns to remove senescent cells, the treatment and recovery effects of skin damage (pain, bruises, swelling, embossing, wounds, scars, etc.) were confirmed, and when each of the test compounds of this example in Table 26 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.57 to 0.71, confirming that there was synergy in efficacy. Similar synergistic results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0256] Furthermore, LX-2102, LX-2201, LX-2301, LX-2302, LX-2305, LX-2306, LX-2307, LX-2308, LX-2309, which are analogues of LX-2002, LX-2003, LX-2005, LX-2007, or LX-2101; LX-2310, LX-2311, LX-2312, LX-2315, LX-2316, LX-2317, LX-2318, LX-2319, LX-2401, LX-2402, LX-2403, LX-2405, LX-2406, LX-2407, LX-2408, Similar skin aging improvement (Example 21-10) and damage treatment and recovery (Example 21-11) effects were confirmed in LX-2409, LX-2501, LX-2502, LX-2503, LX-2505, LX-2506, LX-2507, LX-2508, LX-2509, LX-2510, LX-2511, LX-2512, LX-2513, LX-2517, or LX-5433, and when LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403 were administered together, the CI (combination index) was 0.61 to 0.89, confirming that there was synergy in efficacy. Similar synergistic results were confirmed when LX-8401 was administered instead of LX-3403 and LX-9422 was administered instead of LX-9423.
[0257] Example 21-12. Improvement of joint diseases (osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, spondylitis, degenerative cartilage disease, kyphosis, etc.)
[0258] RNA was extracted from joint tissues as described in WO2023-085787 A1 Example 7-2, and qRT-PCR was performed using synthesized cDNA. The table below quantitatively shows the degree of joint aging according to the amount of mRNA of arthritis indicators in aged mice without and with test compounds. In addition, hotplate analysis was performed to analyze joint pain due to joint aging. Specifically, for thermal pain threshold measurement, mice were acclimated to a temperature of 30°C for 10 minutes using a hot plate, and then the time for a reaction such as licking the hind paw or jumping was measured at 55°C. The response measurement was performed for 30 seconds or less to prevent tissue damage, and the average value was used after measuring five times.
[0259]
[0260] As a result, as shown in the table above, when the test compound was treated in mice in which aging was induced, the amount of type II collagen, a cartilage-forming gene, increased and the time of pain response to heat decreased. In addition, p16, a senescence-related marker in joint tissues, and senescence-associated secretory factor (SASP) and MMP13, a collagen-degrading enzyme, also decreased by treatment with the test compound. From this, it was confirmed that the test compound improved joint diseases caused by joint aging in mice, such as osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, degenerative cartilage disease, and kyphosis, by eliminating senescent cells that increase with aging in mice. Furthermore, similar improvement results were confirmed when LX-401 or LX-405, which are similar to LX-403, LX-5401, or LX-5411, were treated.
[0261] Furthermore, when each of the test compounds of this example in Table 27 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.70 to 0.85, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0262] Example 21-13. Improvement of cardiac disorders and diseases (cardiac load resistance, cardiomegaly, myocardial infarction, heart failure, etc.)
[0263] At the histological level, cardiac aging is characterized by the loss of ventricular cardiomyocytes due to a decreased ability to replace apoptotic or necrotic cardiomyocytes, leading to hypertrophy of the remaining cardiomyocytes. To assess age-related cardiomyocyte hypertrophy, frozen cardiac tissue sections were stained with hematoxylin / eosin (H / E), and the thickness of ventricular cardiomyocytes was observed under a light microscope.
[0264] Additionally, cardiac aging is characterized by decreased stress tolerance, which is associated with ATP-sensitive potassium (K ATP ) channel expression is known to decrease. RNA was extracted from heart tissue as described in WO2023-085787 A1 Example 7-2 and cDNA was synthesized using K ATP qRT-PCR of Sur2a, a regulatory subunit of the channel, was performed.
[0265] The table below quantitatively shows the degree of cardiac aging according to ventricular cardiomyocyte size and Sur2a mRNA amount in mice that were naturally aged and were not treated with the test compound.
[0266]
[0267] As a result, as shown in the table above, when the test compound was treated in mice with induced aging, the mRNA amount of sur2a, an indicator of cardiac stress tolerance, increased and the size of ventricular cardiomyocytes decreased. In addition, p16, an aging-related marker in cardiac tissue, was also reduced by treatment with the test compound. From this, it was confirmed that the test compound improved geriatric cardiac disorders and diseases (cardiac load resistance, cardiac hypertrophy, myocardial infarction, heart failure, etc.) due to cardiac aging in mice by eliminating senescent cells that increase with aging in mice.
[0268] Furthermore, when each of the test compounds of this example in Table 28 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.54 to 0.79, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0269] Example 21-14. Improvement of bone diseases (osteoporosis, fracture healing disorders, alveolar bone loss, periodontal disease, etc.)
[0270] Osteoporosis, a metabolic bone disease characterized by decreased bone density and a high fracture risk, occurs in both men and women with aging. The accumulation of senescent cells is known to contribute to osteoporosis by increasing osteoclast-mediated bone resorption and decreasing osteoblast-mediated bone formation through the senescence-associated secretory factor (SASP). RNA was extracted from the left femur of mice as described in WO2023-085787 A1, Example 7-2, and qRT-PCR was performed using synthesized cDNA. The table below quantitatively shows the mRNA levels of osteoclast markers Ctsk, Ocstamp, Oscar, Rank, and Trap in mice that were naturally aged without and with test compounds. The amount of each factor after aging was calculated as 100% and compared with the amount of each factor after treatment with the test compound.
[0271]
[0272] As a result, as shown in the table above, treatment of mice with aging-induced osteoclast markers decreased the expression of the test compound. Furthermore, p16, a aging-related marker in bone tissue, was also reduced by treatment with the test compound. From this, it was confirmed that the test compound can improve age-related bone diseases such as osteoporosis, fracture healing disorders, and periodontal diseases such as alveolar bone loss by inhibiting bone resorption due to bone aging in mice by eliminating senescent cells that increase with aging.
[0273] Furthermore, when each of the test compounds of this example in Table 29 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.67 to 0.82, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0274] Example 21-15. Improvement of eye diseases (cataracts, etc.)
[0275] Cataracts, which occur with aging, are a disease that causes vision impairment due to clouding of the lens of the eye and is a major cause of blindness. The mice of Example 21-1 were administered the test compound mixed in PBS orally twice a week at a concentration of 360 mg / kg. Cataract development was assessed biweekly until death. The table below shows the incidence of cataracts in mice that had undergone natural aging, untreated and treated with the test compound.
[0276]
[0277] As a result, as shown in the table above, when the test compound was treated in mice in which aging was induced, the incidence of cataracts decreased. In addition, p16, which is an aging-related marker in ocular tissues, and senescence-associated secretory factor (SASP) and MMP13, a collagen-degrading enzyme, were also reduced by treatment with the test compound. From this, it was confirmed that the test compound suppressed the development of cataracts due to ocular aging in mice by eliminating senescent cells that increase with aging in mice. Furthermore, similar improvement results were confirmed when LX-401 or LX-405, which are similar to LX-403, LX-5401, or LX-5411, were treated.
[0278] Furthermore, when each of the test compounds of this example in Table 30 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.59 to 0.78, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0279] Example 22. Removal of senescent cells and related aging inhibition activity in aging mice induced by external stress such as anticancer drugs.
[0280] Example 22-1. Establishment of an anticancer drug-induced aging mouse model
[0281] Eight-week-old male C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) were acclimated to the experimental environment for one week, and then the anticancer drug doxorubicin was administered intraperitoneally at a concentration of 10 mg / kg to induce aging for more than 10 days. The aging-induced mice were randomly assigned to experimental and control groups. LX-403 was mixed with a 10% ethanol solution of PEG400 and administered orally at a concentration of 25 mg / kg daily for 21 days or administered subcutaneously at a concentration of 1 μM. LX-1801 was mixed with distilled water containing 4% DMSO, 30% PEG300, and 5% Tween80 and administered subcutaneously at a concentration of 0.4 μM daily for 21 days. LX-2001 was mixed with PBS and administered subcutaneously at a concentration of 2 μM daily for 21 days. LX-2002 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 2 μM daily for 21 days. LX-2003 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 10 μM daily for 21 days. LX-2005 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 90 μM daily for 21 days. LX-2007 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 90 μM daily for 21 days. LX-2707 was mixed in corn oil and administered orally at a concentration of 600 mg / kg daily for 21 days. LX-3001 was mixed in PBS and administered orally at a concentration of 300 mg / kg daily for 21 days. LX-3002 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% tween80 and administered orally at a concentration of 10 mg / kg daily for 21 days. LX-5401 was mixed in 5% PBS and administered intraperitoneally at a concentration of 50 mg / kg daily for 21 days or administered intradermally at a concentration of 10 μM.LX-5411 was mixed in 5% phosphate-buffered saline (PBS) and administered orally at a concentration of 10 mg / kg daily for 21 days or intradermally at a concentration of 3 μM. LX-5701 was mixed in PBS and administered orally at a concentration of 360 mg / kg daily for 21 days. LX-6807 was mixed in saline and administered intraperitoneally at a concentration of 1 mg / kg daily for 21 days. The control group received only the solution in the same volume. After the end of drug administration, the methods described in each example below were performed.
[0282] Example 22-2. Reduction in the amount of aging-related markers (p16, p21)
[0283] WO2023-085787 A1 Mice were sacrificed in the same manner as in Example 7-2. RNA was extracted from the organ tissues of each part, and qRT-PCR was performed and analyzed using the synthesized cDNA. The table below shows the results showing the mRNA amounts of p16 and p21, which are senescence-related markers, under conditions in which senescence was induced by anticancer treatment and LX-5701 was not treated and was treated. The mRNA amounts of p16 and p21 after senescence induction were calculated as 100% and compared with the mRNA amounts of p16 and p21 after LX-5701 treatment.
[0284]
[0285] As a result, as shown in the table above, when LX-5701 was treated in mice in which aging was induced by anticancer treatment, the mRNA amounts of p16 and p21 decreased in various organ tissues. From this, it was confirmed that LX-5701 effectively reduces the amounts of p16 and p21, which are aging-related markers that increase in various organ tissues of mice, by eliminating senescent cells that increase in mice due to anticancer treatment.
[0286] Example 22-3. Reduction in the amount of aging-related marker (SA-β-gal)
[0287] WO2023-085787 A1 Mice described in Example 7-3 were sacrificed in the same manner, and tissue sections were prepared from the organ tissues of each part and stained for SA-β-gal, a senescence-related marker. The table below shows the results showing the staining area of SA-β-gal, a senescence-related marker, under conditions in which senescence was induced by treatment with an anticancer agent and LX-5701 was not treated and was treated.
[0288]
[0289] As a result, as shown in the table above, when LX-5701 was treated in mice in which aging was induced by anticancer treatment, the staining area of SA-β-gal in various organ tissues decreased. From this, it was confirmed that LX-5701 effectively reduces the amount of SA-β-gal, an aging-related marker that increases in various organ tissues of mice, by eliminating senescent cells that increase with aging in mice by anticancer treatment.
[0290] Example 22-4. Reduction in the amount of age-related degenerative markers (lipofuscin)
[0291] WO2023-085787 A1 Example 7-4 In the same manner as in Example 7-4, mice were sacrificed, and tissue sections were prepared from muscle tissue and stained for lipofuscin, a marker of aging-related degeneration. The table below shows the stained area of lipofuscin, a marker of aging-related degeneration, under conditions in which aging was induced by treatment with an anticancer agent and LX-5701 was not treated and was treated.
[0292]
[0293] As a result, as shown in the table above, when LX-5701 was treated in mice in which aging was induced by anticancer treatment, the staining area of lipofuscin in the muscle tissue decreased. From this, it was confirmed that LX-5701 effectively reduces the amount of lipofuscin, an aging-related degenerative marker that increases in the muscle tissue of mice, by eliminating senescent cells that increase with aging in mice due to anticancer treatment.
[0294] Example 22-5. Reduction in the amount of senescence-associated secretory factor (SASP)
[0295] WO2023-085787 A1 The amount of IL6, a senescence-associated secretory factor (SASP), was measured in serum collected from mice in the same manner as in Example 7-5 using an enzyme-linked immunosorbent assay (ELISA Kit, purchased from R&D Systems). The table below shows the results showing the amount of IL6, a senescence-associated secretory factor (SASP), under conditions in which senescence was induced by treatment with an anticancer agent and LX-5701 was not treated and was treated.
[0296]
[0297] As a result, as shown in the table above, when LX-5701 was treated in mice in which aging was induced by anticancer treatment, the amount of IL6 in the serum decreased. From this, it was confirmed that LX-5701 effectively reduces the amount of IL6, a senescence-associated secretory factor (SASP) that increases in the serum, by eliminating senescent cells that increase with aging in mice due to anticancer treatment.
[0298] Example 22-6. Reduction in the amount of senescence-associated secretory factor (SASP)
[0299] WO2023-085787 A1 Using cDNA synthesized in the same manner as Example 7-6, qRT-PCR was performed and analyzed for IL6, CXCL1, CXCL10, IL1β, etc., which are senescence-associated secretory factors (SASPs). The table below shows the mRNA amounts of IL6, CXCL1, CXCL10, and IL1β, which are senescence-associated secretory factors (SASPs), under conditions in which senescence was induced by anticancer treatment and LX-5701 was not treated and treated. The mRNA amount of each factor after senescence was induced was calculated as 100% and compared with the mRNA amount of each factor after LX-5701 treatment.
[0300]
[0301] As a result, as shown in the table above, when LX-5701 was treated in mice in which aging was induced by anticancer treatment, the mRNA amount of each senescence-associated secretory factor (SASP) decreased in various organ tissues. From this, it was confirmed that LX-5701 effectively reduces the amount of IL6, CXCL1, CXCL10, and IL1β, which are senescence-associated secretory factors (SASPs) that increase in various organ tissues of mice, by eliminating senescent cells that increase with aging of mice due to anticancer treatment.
[0302] Example 22-7. Improvement of fatigue and weakness, and weight loss
[0303] WO2023-085787 A1 In order to analyze fatigue and weakness caused as side effects by anticancer drug treatment in mice, an activity evaluation (open field test), an endurance evaluation (wire hanging test), and a muscle and grip strength evaluation (grip strength test) were performed in the same manner as in Example 7-7. The table below shows the results quantitatively showing the criteria for senescence, activity, endurance, muscle strength, and grip strength, under conditions in which aging was induced by anticancer drug treatment and the test compound was not treated and was treated. The amount of each evaluation after aging was induced was calculated as 100%, and compared with the amount of each evaluation after treatment with the test compound.
[0304]
[0305] As a result, as shown in the table above, when the test compound was treated in mice that had been aging due to anticancer treatment, activity, endurance, muscle strength, and grip strength increased, and body weight loss was improved. In addition, lipofuscin, an age-related degenerative marker in muscle tissue, was also reduced by treatment with the test compound. From this, it was confirmed that the test compound eliminated senescent cells that increased with the aging of the mice due to anticancer treatment, thereby improving fatigue and weakness in the mice that occurred as side effects of anticancer treatment. Consistent with this improvement effect, it was confirmed that the test compound increased the body weight of mice aged due to anticancer treatment.
[0306] Furthermore, when each of the test compounds of this example in Table 36 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.64 to 0.78, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0307] Example 22-8. Improvement of liver damage
[0308] WO2023-085787 A1 Example 7-5 In the same manner as in Example 7-5, the amounts of AST (aspartate aminotransferase) and ALT (alanine transaminase), which are released into the blood when the liver is damaged, were measured by spectrophotometry using a kit (purchased from Sigma) according to the method described in the manufacturer's instructions. The table below shows the results showing the amounts of AST and ALT, which are markers of liver damage, under conditions in which aging was induced by treatment with an anticancer agent and the test compound was not treated and was treated. The amount of each factor after aging was induced was calculated as 100% and compared with the amount of each factor after treatment with the test compound.
[0309]
[0310] As a result, as shown in the table above, treatment of mice induced to age by anticancer treatment with the test compound resulted in a decrease in serum AST and ALT levels. This confirms that the test compound improves liver damage and dysfunction in mice by eliminating senescent cells that increase with age in mice treated with anticancer agents.
[0311] Furthermore, when each of the test compounds of this example in Table 37 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.59 to 0.87, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0312] Example 22-9. Improvement of kidney damage
[0313] WO2023-085787 A1 The amounts of urea and creatinine, which are markers of kidney damage, were measured spectrophotometrically in serum collected from mice using the same method as in Examples 7-8. The table below shows the results of quantitatively showing the levels of urea, creatinine, and Agtr1a mRNA, which are markers of kidney damage, under conditions in which aging was induced by treatment with an anticancer agent and the test compound was not treated and was treated. The amount of each factor after aging was induced was calculated as 100% and compared with the amount of each factor after treatment with the test compound.
[0314]
[0315] As shown in the table above, treatment of mice induced to age by anticancer treatment with the test compound resulted in decreased levels of urea, creatinine, and Agtr1a mRNA. This confirms that the test compound improves renal damage and dysfunction in mice by eliminating senescent cells that increase with age in mice treated with anticancer agents.
[0316] Furthermore, when each of the test compounds of this example in Table 38 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.69 to 0.85, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0317] Example 22-10. Improvement of thrombosis
[0318] Thrombosis is a common side effect of radiation and genotoxic chemotherapy, significantly increasing the risk of death after treatment and reducing quality of life through symptoms such as acute myocardial infarction, stroke, pulmonary thrombosis, acute peripheral arterial occlusion, deep vein thrombosis, portal vein thrombosis, acute renal vein occlusion, cerebral venous sinus thrombosis, and central retinal vein occlusion.
[0319] WO2023-085787 A1 Using cDNA synthesized in the same manner as Example 7-6, qRT-PCR was performed and analyzed for the senescence-associated secretory factor (SASP) produced in the liver and hemostasis-related factors Serpine1 (PAI1), Plau (Urokinase), and TIMP1. In addition, to confirm whether it actually affects hemostasis in vivo, the tail bleeding time was analyzed in mice induced to age by administration of anticancer drugs. Specifically, for the tail bleeding analysis, the mice were anesthetized, the tail was incised 5 mm from the tip with a razor blade, and the bleeding tail was placed in a 15 ml test tube containing saline preheated to 37°C, and the time until blood flow stopped was measured. The bleeding time was determined when bleeding stopped for 10 seconds. The table below shows the results showing the mRNA amounts of hemostasis-related factors and tail bleeding times under conditions in which senescence was induced by treatment with an anticancer drug and the test compound was not treated and was treated. The qPT-PCR results were calculated as 100% of the amount of each factor after aging was induced, and compared with the amount of each factor after treatment with the test compound.
[0320]
[0321] As a result, as shown in the table above, when the test compound was administered to mice induced to age by anticancer treatment, the levels of Serpine1, Plau, and TIMP1 mRNA decreased, and blood coagulation was actually inhibited, increasing tail amputation bleeding time. From this, it was confirmed that the test compound ameliorated thrombosis, a side effect of anticancer therapy, by eliminating senescent cells that increase with the aging of mice due to anticancer treatment.
[0322] Furthermore, when each of the test compounds of this example in Table 39 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.56 to 0.73, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0323] Example 22-11. Improvement of hair loss
[0324] Alopecia is one of the most troubling side effects of chemotherapy, for which there is currently no treatment. Hair loss in mice induced by chemotherapy was quantified using imaging software such as ImageJ (NIH) from digital photographs taken using a fixed camera position and magnification. The table below shows the percentage of areas affected by hair loss in mice induced by chemotherapy, untreated and treated with the test compound.
[0325]
[0326] As a result, as shown in the table above, when the test compound was treated in mice that had undergone aging due to anticancer treatment, the extent of hair loss was reduced. From this, it was confirmed that the test compound improved hair loss in mice by eliminating senescent cells that increase with aging due to anticancer treatment. Furthermore, similar improvement results were confirmed when LX-401 or LX-405, which are similar to LX-403, LX-5401, or LX-5411, were treated.
[0327] Furthermore, when each of the test compounds of this example in Table 40 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.69 to 0.88, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0328] Example 22-12. Improvement of bone marrow dysfunction (myelodysplastic syndrome, myelopathy, bone marrow transplant failure, anemia, etc.)
[0329] Damage to the immune system, including bone marrow, after chemotherapy is known to induce inflammatory responses and contribute to drug resistance and side effects. To analyze the function of bone marrow hematopoietic cells in mice induced to age by anticancer drugs, a cobblestone-area-forming-cell (CAFC) assay was performed. Specifically, bone marrow cells (BMCs) were collected from the femurs and tibias of mice, and BM-MNCs (mono-nuclear cells) were cultured in MethoCult® GF M3434 methylcellulose medium (Stem Cell® Technologies Inc, Canada). FBMD-1 stromal cells were seeded in each well of a 96-well plate to prepare a support cell stromal layer. After 1 week, BM-MNCs were diluted in CAFC medium and added to the support cell stromal layer for co-culture. After 5 weeks of culture, CAFCs were counted under a light microscope. The table below shows the 10 conditions in which mice were not treated with the test compound and were aging-induced with an anticancer agent. 5 The values of CAFC per BMC are shown.
[0330]
[0331] As a result, as shown in the table above, treatment of mice induced to age by anticancer treatment with the test compound resulted in an increase in CAFC, which reflects the degree of hematopoietic stem cell (HSC) proliferation and differentiation. This confirms that the test compound improves bone marrow function in mice by eliminating senescent cells that increase with age in anticancer treatment.
[0332] Furthermore, when each of the test compounds of this example in Table 41 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.65 to 0.84, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0333] Example 23. Removal of senescent cells and related aging inhibition activity in aging mice induced by metabolic disturbances such as obesity.
[0334] Example 23-1. Establishment of an obesity-induced aging mouse model
[0335] WO2023-085787 A1 15-week-old male C57BL6J mice (purchased from Jackson Laboratory) induced to become obese by a high-fat diet in the same manner as Example 9-1 were acclimated to the experimental environment for one week, and then randomly assigned to experimental and control groups. LX-2707 was mixed with corn oil and administered orally at a concentration of 600 mg / kg daily for 21 days. LX-3001 was mixed with PBS and administered orally at a concentration of 300 mg / kg daily for 21 days. LX-3002 was mixed with distilled water containing 4% DMSO, 30% PEG300, and 5% tween80 and administered orally at a concentration of 10 mg / kg daily for 21 days. LX-5701 was mixed with PBS and administered orally at a concentration of 360 mg / kg daily for 21 days. LX-6807 was mixed with saline and administered intraperitoneally at a concentration of 1 mg / kg daily for 21 days. The control group received only the solution in the same volume. After completion of drug administration, the methods described in each example below were performed.
[0336] Example 23-2. Reduction in the amount of aging-related markers (p16, p21)
[0337] WO2023-085787 A1 In the same manner as Example 7-2, mice were sacrificed, RNA was extracted from the organ tissues of each part, and qRT-PCR (quantitative real-time PCR) was performed and analyzed using the synthesized cDNA. The table below shows the results showing the mRNA amounts of p16 and p21, which are aging-related markers, under conditions in which aging was induced by obesity and LX-5701 was not treated and was treated. The mRNA amounts of p16 and p21 after obesity was induced were calculated as 100% and compared with the mRNA amounts of p16 and p21 after LX-5701 treatment.
[0338]
[0339] As a result, as shown in the table above, when LX-5701 was treated in mice in which aging was induced by aging, the mRNA amounts of p16 and p21 decreased in various organ tissues. From this, it was confirmed that LX-5701 effectively reduces the amounts of p16 and p21, which are aging-related markers that increase in various organ tissues of mice, by eliminating senescent cells that increase in mice due to aging caused by obesity.
[0340] Example 23-3. Reduction in the amount of senescence-associated secretory factor (SASP)
[0341] WO2023-085787 A1 The amounts of IL6 and activin A, which are senescence-associated secretory factors (SASPs), were measured in serum collected from mice in the same manner as in Example 7-5 using an enzyme-linked immunosorbent assay (ELISA Kit, purchased from R&D Systems). The table below shows the results showing the amounts of IL6 and activin A, which are senescence-associated secretory factors (SASPs), under conditions in which obesity induced aging and LX-5701 was not treated and was treated.
[0342]
[0343] As a result, as shown in the table above, when LX-5701 was treated in mice induced to age due to obesity, the amounts of IL6 and activin A in the serum decreased. From this, it was confirmed that LX-5701 effectively reduces the amounts of IL6 and activin A, which are senescence-associated secretory factors (SASPs) that increase in the serum of mice, by eliminating senescent cells that increase with aging in mice due to obesity.
[0344] Example 23-4. Improvement of neuropsychiatric disorders (anxiety, depression, lethargy, etc.)
[0345] It was found that anxiety and depression caused by obesity are not causally related to increased body weight, but are caused by the accumulation of senescent cells. Accordingly, an activity evaluation (open field test) was performed to analyze lethargy caused by anxiety and depression in mice by the same method as in Example 7-7 of WO2023-085787 A1. The table below shows the results quantitatively showing the activity, which is a criterion for judging lethargy caused by anxiety and depression, under conditions in which aging was induced by obesity and the test compound was not treated and was treated. The amount of activity evaluation after aging was induced by obesity was calculated as 100% and compared with the amount of activity evaluation after treatment with the test compound.
[0346]
[0347] As a result, as shown in the table above, when the test compound was treated in mice in which aging was induced by obesity, activity increased. From this, it was confirmed that the test compound improved anxiety, depression, and lethargy in mice caused by obesity by removing senescent cells that increase with aging of mice due to obesity. It was confirmed that when LX-401, LX-405, LX-2101, LX-2707, LX-3403, LX-5401, LX-5411, LX-6806, LX-6807, LX-9118, LX-9423, or LX-9744 was treated, senile depression was similarly improved by removing senescent cells.
[0348] Furthermore, when each of the test compounds of this example in Table 44 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.59 to 0.74, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0349] Example 23-5. Improvement of fatty liver (alcoholic / non-alcoholic fatty liver disease, hepatic steatosis, etc.)
[0350] Mice were sacrificed, and liver tissue sections were prepared in the same manner as in WO2023-085787 A1 Example 7-3, and fat accumulation was stained with Oil Red O. In addition, AST and ALT, which are indicators of liver damage, were measured in the same manner as in WO2023-085787 A1 Example 8-8. The table below shows the results of the staining area of Oil Red O, which is a criterion for determining fatty liver, and the measured amount of the liver damage indicator due to fatty liver, under conditions in which aging was induced by obesity and the test compound was not treated and was treated. The staining area of Oil Red O and the amount of the liver damage indicator after aging was induced by obesity were calculated as 100%, and compared with the values after treatment with the test compound.
[0351]
[0352] As a result, as shown in the table above, when the test compound was treated in mice induced to age due to obesity, the staining area of Oil Red O and the levels of serum AST and ALT, indicators of liver damage, decreased. From this, it was confirmed that the test compound reduced the amount of fat accumulated in the liver tissue of the mice and improved hepatic steatosis by eliminating senescent cells that increase with the aging of the mice due to obesity.
[0353] Furthermore, when each of the test compounds of this example in Table 45 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.64 to 0.89, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0354] Example 23-6. Improvement of diabetes and diabetic complications (diabetic ulcers, diabetic retinopathy, diabetic cardiomyopathy, diabetic nephropathy, etc.)
[0355] WO2023-085787 A1 Hyperglycemia and glycated hemoglobin (HbA1c), a diabetes marker, were measured in serum collected from mice using the same method as in Example 7-5. In addition, the improvement effect on diabetic foot ulcer and diabetic retinopathy, which are major complications of diabetes, was analyzed. Specifically, a diabetic foot ulcer model was created by creating a full-thickness 5 mm x 5 mm wound on the skin of the left dorsal paw of a mouse induced with obesity-induced diabetes, and the wound size was measured under conditions where the test compound was not treated and was treated to analyze the healing effect. In addition, the mRNA amount of VEGF, a marker of angiogenesis in retinopathy, was measured from the eye by qRT-PCR as described in WO2023-085787 A1 Example 7-2. The qPT-PCR results were calculated as 100% of the amount of each factor after aging was induced, and compared with the amount of each factor after treatment with the test compound.
[0356]
[0357] As a result, as shown in the table above, when the test compound was treated in mice with diabetes induced by obesity, the amount of serum glycated hemoglobin (HbA1c) decreased, the size of the wound on the dorsum of the foot decreased, and the amount of VEFG mRNA in the ocular tissue decreased. In addition, p16 and p21, which are aging-related markers in the skin, heart, and ocular tissues, were also decreased by treatment with the test compound. From this, it was confirmed that the test compound reduces diabetic symptoms induced in mice and improves diabetic complications such as diabetic ulcers, diabetic retinopathy, diabetic cardiomyopathy, and diabetic nephropathy by eliminating senescent cells that increase with aging in mice due to obesity.
[0358] Furthermore, when each of the test compounds of this example in Table 46 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.72 to 0.85, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0359] Example 24. Improvement of fibrosis and sclerosis
[0360] Example 24-1. Improvement of fibrosis
[0361] Eight-week-old male C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) were acclimated to the experimental environment for one week, and then bleomyxin, an anticancer drug, was administered by intratracheal inhalation at a concentration of 2.5 mg / kg to induce aging for more than 10 days. The aging-induced mice were randomly assigned to experimental and control groups. LX-2707 was mixed with corn oil and administered orally at a concentration of 600 mg / kg daily for 21 days. LX-3001 was mixed with PBS and administered orally at a concentration of 300 mg / kg daily for 21 days. LX-3002 was mixed with distilled water (4% DMSO, 30% PEG300, 5% tween80) and administered orally at a concentration of 10 mg / kg daily for 21 days. LX-5701 was mixed with PBS and administered orally at a concentration of 360 mg / kg daily for 21 days. LX-6807 was mixed in saline and administered intraperitoneally at a concentration of 1 mg / kg daily for 21 days. The control group was administered only the solution in the same volume. After the end of drug administration, mice were sacrificed in the same manner as in Example 7-2 of WO2023-085787 A1, RNA was extracted from lung tissue, and qRT-PCR (quantitative real-time PCR) was performed and analyzed using the synthesized cDNA. The table below shows the results of the mRNA amounts of p16, a senescence-related marker, and IL6 and Col1a1, senescence-related secretory factors, under conditions in which senescence was induced and the test compound was not treated and treated. The mRNA amount after senescence induction was calculated as 100% and compared with the results after test compound treatment. In addition, paraffin sections were stained with H / E (Hematoxylin / Eosin) and the size of the alveoli was measured under an optical microscope to evaluate the degree of lung function damage due to pulmonary fibrosis.
[0362]
[0363] As a result, as shown in the table above, when the test compound was treated in mice with lung aging induced by anticancer agents, the amount of aging-related markers and markers of inflammation and fibrosis decreased, and the average size of the dilated alveoli decreased due to loss of elasticity and rebound force caused by pulmonary fibrosis. From this, it was confirmed that the test compound reduced pulmonary fibrosis induced in mice and improved pulmonary dysfunction by eliminating senescent cells that increase with aging.
[0364] Furthermore, when each of the test compounds of this example in Table 47 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.67 to 0.82, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0365] Example 24-2. Improvement of sclerosis
[0366] 8-week-old male C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) were acclimated to the experimental environment for 1 week, and then 100 μl of bleomyxin, an anticancer drug, was administered subcutaneously at a concentration of 1 mg / ml every other day to induce scleroderma for more than 3 weeks. Mice with scleroderma were randomly assigned to experimental and control groups. LX-403 was mixed with a 10% ethanol solution of PEG400 and administered orally at a concentration of 25 mg / kg daily for 21 days or administered directly to the skin at a concentration of 1 μM. LX-1801 was mixed with distilled water containing 4% DMSO, 30% PEG300, and 5% Tween80 and administered subcutaneously at a concentration of 0.4 μM daily for 21 days. LX-2001 was mixed with PBS and administered subcutaneously at a concentration of 2 μM daily for 21 days. LX-2002 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 2 μM daily for 21 days. LX-2003 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 10 μM daily for 21 days. LX-2005 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 90 μM daily for 21 days. LX-2007 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intradermally at a concentration of 90 μM daily for 21 days. LX-2707 was mixed in corn oil and administered orally at a concentration of 600 mg / kg daily for 21 days. LX-3001 was mixed in PBS and administered orally at a concentration of 300 mg / kg daily for 21 days. LX-3002 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% tween80 and administered orally at a concentration of 10 mg / kg daily for 21 days. LX-5401 was mixed in 5% PBS and administered intraperitoneally at a concentration of 50 mg / kg daily for 21 days or administered intradermally at a concentration of 10 μM.LX-5411 was mixed with 5% PBS and administered orally at a concentration of 10 mg / kg daily for 21 days or administered subcutaneously at a concentration of 3 μM. LX-5701 was mixed with PBS and administered orally at a concentration of 360 mg / kg daily for 21 days. LX-6807 was mixed with saline and administered intraperitoneally at a concentration of 1 mg / kg daily for 21 days. The control group received only the solution in the same volume. After the end of drug administration, mice were sacrificed in the same manner as in Example 7-2 of WO2023-085787 A1, RNA was extracted from skin tissue, and the synthesized cDNA was used to perform and analyze the mRNA amounts of p16 and collagen (COL1A1) by qRT-PCR (quantitative real-time PCR). Additionally, to measure the degree of bleomycin-induced skin hardening, skin frozen sections were stained with hematoxylin / eosin (H / E), and the dermal thickness was observed under an optical microscope. The table below quantitatively shows the mRNA amounts and dermal thickness in mice with scleroderma induced under untreated and treated conditions with the test compound.
[0367]
[0368] As a result, as shown in the table above, when the test compound was treated in mice with scleroderma induced by an anticancer agent, the amount of aging-related markers and fibrosis markers decreased, and the thickness of the skin thickened by scleroderma decreased. From this, it was confirmed that the test compound improved scleroderma induced in mice by eliminating senescent cells that increase with aging. Furthermore, similar improvement results were confirmed when LX-401 or LX-405, which are similar to LX-403, LX-5401, or LX-5411, were treated.
[0369] Furthermore, when each of the test compounds of this example in Table 48 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.61 to 0.76, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0370] Example 25. Improvement of pulmonary dysfunction and diseases (chronic obstructive pulmonary disease, emphysema, etc.)
[0371] 8-week-old male C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) were acclimated to the experimental environment for 1 week, and then exposed to standard cigarette smoke (Costa monitoring cigarette 7) for 5 hours a day, 5 days a week for 6 months to induce chronic obstructive pulmonary disease (COPD). COPD-induced mice were randomly assigned to experimental and control groups. LX-2707 was mixed with corn oil and administered orally at a concentration of 600 mg / kg daily for 21 days. LX-3001 was mixed with PBS and administered orally at a concentration of 300 mg / kg daily for 21 days. LX-3002 was mixed with distilled water containing 4% DMSO, 30% PEG300, and 5% tween80 and administered orally at a concentration of 10 mg / kg daily for 21 days. LX-5701 was mixed in PBS and administered orally at a concentration of 360 mg / kg daily for 21 days. LX-6807 was mixed in saline and administered intraperitoneally at a concentration of 1 mg / kg daily for 21 days. The control group received only the solution in the same volume. After the end of drug administration, mice were sacrificed in the same manner as in Example 7-2 of WO2023-085787 A1, RNA was extracted from lung tissue, and qRT-PCR (quantitative real-time PCR) was performed and analyzed using the synthesized cDNA. The table below shows the results showing the mRNA amounts of p16, a senescence-related marker, and IL6, a senescence-related secretory factor, under conditions in which senescence was induced and the test compound was not treated and treated. The mRNA amount after senescence was induced was calculated as 100%, and the results after treatment with the test compound were compared. Additionally, paraffin sections were stained with H / E (Hematoxylin / Eosin) and the size of alveoli was measured under an optical microscope to evaluate the degree of lung function damage.
[0372]
[0373] As a result, as shown in the table above, treatment of mice with lung disease induced by cigarette smoke with the test compound resulted in a decrease in the amount of aging-related and inflammatory markers, and a decrease in the average size of dilated alveoli. From this, it was confirmed that the test compound suppressed lung aging and inflammation and improved lung function impairment due to chronic obstructive pulmonary disease induced by cigarette smoke exposure in mice by eliminating senescent cells that increase with aging.
[0374] Furthermore, when each of the test compounds of this example in Table 49 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.61 to 0.82, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0375] Example 26. Improvement of liver diseases and disorders (liver fibrosis, cirrhosis, hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, bile duct damage, etc.)
[0376] Eight-week-old male C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) were allowed to adapt to the experimental environment for one week, and then carbon tetrachloride (CCL4) was administered intraperitoneally at a concentration of 0.5 μl / g to induce aging for more than 6 weeks. The aging-induced mice were randomly divided into experimental and control groups. LX-2707, LX-3001, LX-3002, LX-5701, and LX-6807 were administered in the same manner as in Example 25. The control group was administered only the solution in the same volume. After the end of drug administration, the mice were sacrificed, and RNA was extracted from the liver in the same manner as in Example 7-2 of WO2023-085787 A1, and qRT-PCR was performed using the synthesized cDNA. The table below shows the levels of mRNA for p16, a senescence-associated marker, and IL6 and Col1a1, senescence-associated secretory factors, as well as serum AST, a liver damage marker, under conditions in which liver damage and disease were induced and treated with the test compound. The mRNA and AST levels after senescence induction were calculated as 100% and compared with the mRNA levels of p16 after treatment with the test compound.
[0377]
[0378] As a result, as shown in the table above, when the test compound was treated in mice with liver fibrosis induced by an anticancer drug, the amount of aging-related and fibrosis markers decreased, and the amount of AST, a liver damage marker, in the blood decreased. From this, it was confirmed that the test compound improved liver damage and diseases induced in mice, such as liver fibrosis, cirrhosis, hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and bile duct damage, by eliminating senescent cells that increase with aging.
[0379] Furthermore, when each of the test compounds of this example in Table 50 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.68 to 0.87, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0380] Example 27. Improvement of vascular disorders and diseases (atherosclerosis, aortic aneurysm, coronary aneurysm, cerebral aneurysm, geriatric vascular dysfunction, etc.)
[0381] WO2023-085787 A1 15-week-old male C57BL6-ApoE mice induced with arteriosclerosis by high-fat diet in the same manner as Example 9-1 - / -- Mice (purchased from SLC) were allowed to adapt to the experimental environment for one week and then randomly assigned to experimental and control groups. LX-2707, LX-3001, LX-3002, LX-5701, and LX-6807 were administered in the same manner as in Example 25. The control group was administered only the solution in the same volume. After drug administration, the mice were sacrificed, and RNA from the aortic arch of the thoracic aorta was extracted in the same manner as in Example 7-2 of WO2023-085787 A1, and qRT-PCR was performed using the synthesized cDNA. In addition, the remaining part of the thoracic aorta was dissected and fixed flat in 4% paraformaldehyde at room temperature for 12 hours, and then the vascular plaque was stained with Oil Red O in the same manner as in Example 23-5. The table below shows the mRNA levels of p16, a senescence-associated marker, and the amount of stained vascular plaques under conditions in which atherosclerosis was induced and the test compound was not administered. The mRNA level after senescence induction was calculated as 100% and compared with the mRNA level of p16 after treatment with the test compound.
[0382]
[0383] As a result, as shown in the table above, when the test compound was administered to mice with atherosclerosis induced by a high-fat diet, the amount of aging-related markers decreased, and the amount of vascular plaque in the thoracic aorta decreased. From this, it was confirmed that the test compound improved vascular aging and diseases induced in mice, such as atherosclerosis, aortic aneurysm, coronary aneurysm, cerebral aneurysm, and age-related vascular dysfunction, by eliminating senescent cells that increase with aging.
[0384] Furthermore, when each of the test compounds of this example in Table 51 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.64 to 0.79, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0385] Example 28. Improvement of degenerative brain diseases (dementia, Alzheimer's disease, memory loss, (mild) cognitive impairment, etc.)
[0386] Twelve-week-old male SAMP8 mice (purchased from SLC), a cognitive impairment model, were allowed to adapt to the experimental environment for one week, and then randomly assigned to experimental and control groups. LX-2707, LX-3001, LX-3002, LX-5701, and LX-6807 were administered in the same manner as in Example 25. LX-2101 was mixed with 5% DMSO (purchased from Sigma) in PBS and administered intraperitoneally at a concentration of 10 mg / kg daily for 21 days. The control group was administered only the solution in the same volume. After drug administration, the Y maze test was performed to analyze the degree of improvement in cognition and memory in the mice. The Y-maze test is a method to evaluate short-term memory-type momentary spatial recognition. It is a Y-shaped enclosed maze made with black acrylic to the specifications (length 40 cm, width 8 cm, height 13 cm, angle of each arm 120 degrees). Three arms were designated A, B, and C, and a mouse was carefully placed on one arm and allowed to move freely for 8 minutes. The arm into which the mouse entered up to its tail was recorded in order. One point (acrual alternation) was awarded for each case in which the mouse entered each arm sequentially. Alternation behavior was defined as entering all arms without overlapping, and spontaneous alternation was calculated using the following equation.
[0387] - Voluntary change action power (%) = actual change / maximum change x100
[0388] - Maximum change: Total number of entries -2
[0389] After behavioral assessment, mice were sacrificed, and RNA from the hippocampus region of the brain was extracted using the same method as in Example 7-2 of WO2023-085787 A1, and qRT-PCR was performed using the synthesized cDNA. The table below shows the results quantitatively showing the mRNA of p16, an aging-related marker, and spontaneous altered behavior, a criterion for determining cognitive impairment, in cognitive impairment model mice untreated and treated with the test compound.
[0390]
[0391] As a result, as shown in the table above, treatment of cognitive impairment model mice with the test compound reduced the amount of p16, a marker associated with aging, and increased spontaneous alterative behavior. This confirms that the test compound improves cognitive and memory impairments induced by dementia, Alzheimer's disease, memory loss, and (mild) cognitive impairment in mice by eliminating senescent cells, which increase with aging.
[0392] Furthermore, when each of the test compounds of this example in Table 52 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.74 to 0.87, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0393] Example 29. Improvement of retinal degenerative diseases (age-related macular degeneration, macular edema, retinopathy, etc.)
[0394] 8-week-old male C57BL6J mice (purchased from KRIBB Laboratory Animal Resource Center) were adapted to the experimental environment for 1 week, and then intravenously administered 20 mg / kg of NaIO3, an oxidizing agent that induces retinal pigment epithelium death and retinal degeneration, to induce retinal degenerative disease for more than 7 days. Mice with retinal degenerative disease were randomly divided into experimental and control groups. LX-403 was mixed with a 10% ethanol solution of PEG400 and administered orally at a concentration of 25 mg / kg daily for 21 days or administered directly into the eye at a concentration of 1 μM. LX-1801 was mixed with distilled water containing 4% DMSO, 30% PEG300, and 5% Tween80 and administered into the eye at a concentration of 0.4 μM daily for 21 days. LX-2001 was mixed in PBS and administered intraocularly at a concentration of 2 μM daily for 21 days. LX-2002 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intraocularly at a concentration of 2 μM daily for 21 days. LX-2003 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intraocularly at a concentration of 10 μM daily for 21 days. LX-2005 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intraocularly at a concentration of 90 μM daily for 21 days. LX-2007 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered intraocularly at a concentration of 90 μM daily for 21 days. LX-2707 was mixed in corn oil and administered orally at a concentration of 600 mg / kg daily for 21 days. LX-3001 was mixed in PBS and administered orally at a concentration of 300 mg / kg daily for 21 days. LX-3002 was mixed in distilled water with 4% DMSO, 30% PEG300, and 5% Tween80 and administered orally at a concentration of 10 mg / kg daily for 21 days.LX-5401 was mixed in 5% phosphate-buffered saline (PBS) and administered intraperitoneally at a concentration of 50 mg / kg daily for 21 days or intraocularly at a concentration of 10 μM. LX-5411 was mixed in 5% phosphate-buffered saline (PBS) and administered orally at a concentration of 10 mg / kg daily for 21 days or intraocularly at a concentration of 3 μM. LX-5701 was mixed in PBS and administered orally at a concentration of 360 mg / kg daily for 21 days. LX-6807 was mixed in saline and administered intraperitoneally at a concentration of 1 mg / kg daily for 21 days. LX-2101 was mixed in 5% DMSO (purchased from Sigma) in PBS and administered intraperitoneally at a concentration of 10 mg / kg daily for 21 days. The control group received only the solution in the same volume. After the end of drug administration, the mice were sacrificed, and RNA was extracted from one eye using the same method as in Example 7-2 of WO2023-085787 A1, and qRT-PCR was performed using the synthesized cDNA. In addition, frozen sections of the other eye tissue were stained with H / E (Hematoxylin / Eosin), and the thickness of the outer nuclear layer (ORL) was observed under an optical microscope. The table below shows the results of the mRNA amount of p16, a senescence-related marker, and the thickness of the ORL under conditions of no and treated test compounds. The mRNA amount after senescence induction was calculated as 100% and compared with the mRNA amount of p16 after treatment with the test compound.
[0395]
[0396] As a result, as shown in the table above, when the test compound was treated in the retinal degenerative disease model mouse, the amount of p16, an aging-related marker, was reduced, and the thickness of the outer nuclear layer thinned by NaIO3 was restored. From this, it was confirmed that the test compound improved retinal degenerative diseases such as age-related macular degeneration, macular edema, and retinopathy induced in the mouse by removing senescent cells that increase with aging. Furthermore, similar improvement results were confirmed when LX-401 or LX-405, which are similar to LX-403, LX-5401, or LX-5411, were treated.
[0397] Furthermore, when each of the test compounds of this example in Table 53 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.61 to 0.79, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0398] Example 30. Improvement of geriatric hypertension
[0399] Ten-week-old male SHR / Izm rats (purchased from SLC), a model of essential hypertension, were allowed to acclimate to the experimental environment for one week, and then randomly assigned to experimental and control groups. LX-2707, LX-3001, LX-3002, LX-5701, or LX-6807 was administered in the same manner as in Example 25. The control group was administered only the solution in the same volume. After drug administration, the blood pressure of the experimental animals was measured, and RNA was extracted from the thoracic aorta in the same manner as in Example 7-2 of WO2023-085787 A1, and qRT-PCR was performed using the synthesized cDNA. The blood pressure of the experimental animals was measured three times by attaching a cuff with a measurement sensor to the caudal vein in a measurement holder, allowing the animals to rest for about 10 minutes, and then using a blood pressure monitor (purchased from IITC). The table below shows the mRNA levels of p16, an aging-related marker, and blood pressure changes in untreated and treated animals with the test compound. The mRNA levels after aging were calculated as 100% and compared with the mRNA levels of p16 after treatment with the test compound.
[0400]
[0401] As shown in the table above, treatment of hypertensive model mice with the test compound resulted in a decrease in the amount of p16, a marker associated with aging, and a decrease in blood pressure. This confirms that the test compound improves aging-induced hypertension in mice by eliminating senescent cells, which increase with aging.
[0402] Furthermore, when each of the test compounds of this example in Table 54 was administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.71 to 0.88, confirming that there was synergy in efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0403] Example 31. Removal of senescent cells and related aging inhibition activity in aging mice (improvement of aging inflammation and geriatric depression, senescence, sarcopenia, lipoatrophy, kidney disease (kidney damage, chronic kidney disease, etc.), skin aging and skin diseases (wrinkles, loss of elasticity, hyperpigmentation, etc.), osteoarthritis, cardiac aging (reduced cardiac load resistance, etc.), bone disease (osteoporosis, etc.), eye disease (cataract, etc.), lung disease (pulmonary fibrosis, etc.), liver disease (liver damage, liver fibrosis, liver cirrhosis, etc.))
[0404] WO2023-085787 A1 In the same manner as Example 7-1, naturally aged mice were administered LX-305 (5% DMSO in Corn Oil, 8 mg / kg, intraperitoneal administration), LX-403 (10% ethanol in PEG400, 25 mg / kg, oral administration), LX-801 (5% DMSO in PBS solution, 75 mg / kg, oral administration), LX-905 (5% DMSO in PBS solution, 100 mg / kg, oral administration), LX-1102 (5% DMSO in Corn Oil, 100 mg / kg oral administration), LX-1103 (PBS, 100 mg / kg intraperitoneal administration), LX-1302 (50% PEG300 in Saline, 320 mg / kg intraperitoneal administration), LX-1601 (50% PEG300 in Saline, 50 mg / kg (Oral administration), LX-1603 (5% DMSO in Corn Oil, 35 mg / kg oral administration), LX-1801 (5% DMSO in PBS solution, 50 mg / kg, intraperitoneal administration), LX-1902 (5% DMSO in PBS solution, 60 mg / kg, oral administration), LX-1903 (5% DMSO in PBS solution, 10 mg / kg, oral administration), LX-2601 (4% DMSO+30% PEG300+5% Tween80 in Saline, 3 mg / kg oral administration), LX-2602 (5% DMSO in Corn Oil, 75 mg / kg intraperitoneal administration), LX-2702 (5% DMSO in Corn Oil, 400 mg / kg oral administration), LX-2901 (4% DMSO+30% PEG300+5% Tween80 in water, 2 mg / kg, (Intraperitoneal administration), LX-3106 (5% DMSO in PBS solution, 50 mg / kg, oral administration), LX-3107 (water, 100 mg / kg, oral administration), LX-3200 (5% DMSO in PBS solution, 10 mg / kg, oral administration), LX-3201 (5% ethanol+10% tween80 in saline, 2.6 mg / kg, subcutaneous administration),LX-3203 (5% DMSO+40% PEG300+5% Tween80 in water, 100 mg / kg oral administration), LX-3303 (10% ethanol in corn oil, LX-5201 (40% PEG400+4% DMSO in PBS solution, 50 mg / kg, intraperitoneal administration), LX-5401 (5% DMSO in PBS solution, 50 mg / kg, intraperitoneal administration), LX-5411 (5% DMSO in PBS solution, 10 mg / kg, intraperitoneal administration), LX-5424 (5% DMSO+45% PEG300+5% Tween80 in Saline, 400 mg / kg intraperitoneal administration), LX-5702 (5% DMSO in PBS solution, 360 mg / kg, oral administration), LX-5706 (5% DMSO in PBS solution, 100 mg / kg, intraperitoneal administration), LX-5707 (5% DMSO in PBS solution, 100 mg / kg, intraperitoneal administration), LX-5711 (5% DMSO in PBS solution, 360 mg / kg, oral administration), LX-5721 (5% DMSO in PBS solution, 360 mg / kg, oral administration), LX-5722 (5% DMSO in PBS solution, 360 mg / kg, oral administration), LX-5731 (5% DMSO in PBS solution, 360 mg / kg, oral administration), LX-8401 (PBS, 10 mg / kg, intraperitoneal administration), LX-6501 (4% DMSO+30% PEG300+5% Tween80 in water, 80 mg / kg intraperitoneal administration), LX-6537 (PBS, 40 mg / kg intraperitoneal administration), LX-6800 (5% DMSO in Corn Oil, 30 mg / kg oral administration), LX-7103 (5% DMSO+45% PEG300+5% Tween80 in Saline, 50 mg / kg intraperitoneal administration), LX-8402 (PBS, 10 mg / kg intraperitoneal administration), LX-8726 (4% DMSO+30% PEG300+5% Tween80 in water, 50 mg / kg oral administration), LX-8801 (PBS, 400 mg / kg oral administration),LX-8805 (4% DMSO+30% PEG300+5% Tween80 in water, 60 mg / kg oral administration), LX-8812 (4% DMSO+30% PEG300+5% Tween80, 200 mg / kg oral administration), LX-9118 (50% PEG300 in Saline, 200 mg / kg oral administration), LX-9421 (5% DMSO+45% PEG300+5% Tween80 in Saline, 30 mg / kg oral administration), and LX-9744 (5% DMSO+45% PEG300+5% Tween80 in Saline, 60 mg / kg oral administration) were administered under designated conditions for 21 days. The control group was administered only the solution in the same volume. After the end of drug administration, the methods described in each example below were performed. WO2023-085787 A1 Liver, kidney, skin, knee joint, heart, and femur tissues were collected from mice in which natural aging was induced in the same manner as in Examples 7-2 and 7-6, and lung tissues were collected from mice in which pulmonary fibrosis was induced in the same manner as in Example 24-1. In addition, liver tissues were collected from mice in which liver fibrosis was induced in the same manner as in Example 26, total RNA was extracted, and qRT-PCR was performed and analyzed using the synthesized cDNA. The table below shows the results showing the mRNA amounts of p16, a senescence-related marker, and MMP3 and IL6, senescence-associated secretory factors (SASPs), in liver tissues of mice in which natural aging was induced in untreated and treated conditions with test compounds. The mRNA amounts of p16, MMP3, and IL6 after natural aging were calculated as 100% and compared with the mRNA amounts of p16, MMP3, and IL6 after treatment with the test compound. Furthermore, an activity assessment (open field test) was performed to analyze aging-related senescence in mice, and agtr1a mRNA analysis was performed to evaluate renal damage and disease.We performed col1a1 and SDF1 mRNA analysis for skin aging evaluation such as wrinkles / elasticity loss / hyperpigmentation, col2a1 mRNA analysis for joint aging evaluation such as osteoarthritis, sur2a mRNA analysis for cardiac aging evaluation such as decreased cardiac load resistance, ctsk mRNA analysis for bone disease evaluation due to aging such as osteoporosis, muscle tissue weight for sarcopenia analysis, adipose tissue weight for lipoatrophy analysis, and cataract incidence analysis. For cataract incidence analysis, the drug was administered twice a week under the conditions specified above, and biweekly examinations were conducted until death. The table below quantitatively shows the results of the evaluation of each item in mice that were induced to undergo natural aging under untreated and treated conditions with the test compound.
[0405]
[0406]
[0407] As a result, as shown in the evaluation results of WO2023-085787 A1 Examples 7-2, 7-6, and 7-5, when mice aged naturally, the amounts of p16, MMP3, and IL6 in the liver tissue increased, but when the test compound was treated, the mRNA amounts of p16, MMP3, and IL6 decreased. From this, it was confirmed that the test compound can improve aging inflammation and geriatric depression by effectively reducing the amounts of p16, a aging-related marker, and MMP3 and IL6, which are aging-associated secretory factors (SASPs), by eliminating senescent cells that increase in mice due to natural aging.
[0408] Furthermore, as shown in the evaluation results of WO2023-085787 A1 Example 7-7, when mice were naturally aged, their activity decreased and the amount of muscle and fat tissue decreased, but when treated with the test compound, their activity and the amount of muscle and fat tissue increased. In addition, the mRNA amounts of Agtr1a, a renal damage marker, and ctsk, an osteoclast marker of the femur, decreased, and the mRNA amounts of type 1 collagen in the skin, type 2 collagen, a marker of cartilage formation in the joints, SDF1, which inhibits pigmentation, and sur2a, a marker of cardiac load resistance, increased, and the incidence of cataracts decreased.
[0409] The table below shows the quantitative results of the evaluation of each item in mice that had pulmonary fibrosis induced by bleomycin, under conditions in which the test compound was not treated and was treated.
[0410]
[0411] As a result, it was confirmed that the test compound improved lung diseases such as pulmonary fibrosis, idiopathic pulmonary fibrosis, emphysema, and pulmonary failure by effectively reducing the mRNA amount of p16, a senescence-related marker, and Cola1, a secretory factor (SASP), by eliminating senescent cells that increase in mice by inducing pulmonary fibrosis.
[0412] The table below shows the quantitative results of the evaluation of each item in mice that had liver fibrosis induced by carbon tetrachloride (CCL4) under conditions in which the test compound was not treated and was treated.
[0413]
[0414] As a result, it was confirmed that the test compound improved liver diseases such as liver fibrosis, cirrhosis, hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, and bile duct damage by effectively reducing the mRNA amount of p16, a senescence-related marker, and Cola1, a secretory factor (SASP), by eliminating senescent cells that increase in mice due to induction of liver fibrosis.
[0415] From this, it was confirmed that the test compound improved senescent inflammation and geriatric depression, senility, sarcopenia, lipoatrophy, kidney disease (kidney damage, chronic kidney disease, etc.), skin aging (wrinkles, loss of elasticity, hyperpigmentation), osteoarthritis, heart aging (reduced cardiac load resistance), senile bone disease (osteoporosis, etc.), senile eye disease (cataracts, etc.), senile lung disease (pulmonary fibrosis, etc.), and senile liver disease (liver damage, liver fibrosis, cirrhosis, etc.) in mice by eliminating senescent cells in each tissue that increase with aging. A similar improving effect was confirmed in senescent cells killed by the test compound.
[0416] Furthermore, when the test compounds of this example in Tables 55, 56, and 57 were administered together with LX-6806, LX-6807, LX-9118, LX-9423, LX-9744, or LX-3403, the CI (combination index) was 0.51 to 0.73, confirming that there was synergy in the anti-aging activity and improvement efficacy. Similar synergy results were confirmed when LX-8401 was administered instead of LX-3403, and LX-9422 was administered instead of LX-9423.
[0417] Example 32. Removal of aged human cells and cancer cells by secretion of cells treated with the compound of the present invention.
[0418] In the same manner as in Example 13, the test compounds were treated at high concentrations of 30 μM and 90 μM, respectively, to obtain culture medium supernatants containing secretions from death-induced senescent cells, and the degree of death of the senescent cells was measured. The cell viability results are shown in the table below.
[0419]
[0420] As a result, it was confirmed that the supernatant containing secretions from cells induced to die by treatment with the test compound can effectively remove senescent cells by inducing the death of senescent cells.
[0421] Furthermore, it was confirmed that the supernatant containing secretions from cells in which death was induced by treatment with the test compound effectively induces death and removes aged cancer cells, as in Example 14.
[0422] In addition, the supernatant obtained through the same process from the medium treated with the test compound without culturing cells (No Cells) did not induce the death of both normally dividing (Proliferating) and senescent cells. From this, it was confirmed that the supernatant containing substances secreted from cells treated with the test compound and induced to die can effectively remove senescent cells by inducing the death of various senescent cells, including cancer cells.
Claims
1. A composition for removing senescent cells, comprising a compound of Table 1 or 2 or a pharmaceutically acceptable salt thereof; a secretion of cells killed by treatment with such compound or a pharmaceutically acceptable salt thereof; or a cell killed by treatment with such compound or a pharmaceutically acceptable salt thereof.
2. A composition for removing senescent cells, wherein the compound of Table 1 or 2 increases the secretion of HMGN1 (High Mobility Group Nucleosome Binding Domain 1) protein (HMG14) in senescent cells.
3. A composition for removing senescent cells, wherein the composition comprises a compound of Table 1 or a pharmaceutically acceptable salt thereof; a secretion of cells killed by treatment with a compound of Table 1 or a pharmaceutically acceptable salt thereof; or a cell killed by treatment with a compound of Table 1 or a pharmaceutically acceptable salt thereof.
4. A composition for removing senescent cells, according to any one of claims 1 to 3, which improves, treats, or prevents diseases and disorders related to senescent cells.
5. A composition for removing senescent cells in claim 4, wherein the disease and disorder associated with the senescent cells is at least one selected from the group consisting of proliferative diseases and disorders, inflammatory or autoimmune diseases and disorders, neurological diseases and disorders, metabolic diseases and disorders, cardiovascular diseases and disorders, pulmonary diseases and disorders, renal diseases and disorders, liver diseases and disorders, ocular diseases and disorders, skin diseases and disorders, regenerative maintenance-related diseases and disorders, transplant-related diseases and disorders, fibrotic diseases and disorders, sclerotic diseases and disorders, β-galactosidase-related diseases and disorders, geriatric diseases and disorders, stress-induced side effects or sequelae and aging-related diseases and disorders caused thereby, and aging-related rare diseases and disorders.
6. In paragraph 4, the proliferative disease and disorder is cancer; the inflammatory or autoimmune disease and disorder is arthritis, osteoarthritis, rheumatoid arthritis, juvenile idiopathic arthritis, spondyloarthritis, degenerative cartilage disease, or kyphosis; the neurological disease and disorder is dementia, Alzheimer's disease, memory loss, or cognitive impairment; the metabolic disease and disorder is obesity, diabetes and diabetic complications (e.g., diabetic ulcer, diabetic retinopathy, diabetic cardiomyopathy, diabetic nephropathy), or geriatric bone disease (e.g., osteoporosis, impaired fracture healing, alveolar bone loss, periodontal disease); the cardiovascular disease and disorder is atherosclerosis, aortic aneurysm, coronary artery aneurysm, cerebral aneurysm, senile vascular dysfunction, decreased cardiac load resistance, cardiac hypertrophy, myocardial infarction, heart failure, or hypertension; The lung disease or disorder is idiopathic pulmonary fibrosis, chronic pulmonary inflammation, pulmonary dysfunction, pulmonary fibrosis, chronic obstructive pulmonary disease, or emphysema; the kidney disease or disorder is nephropathy, renal failure, glomerulosclerosis, or chronic kidney disease; the liver disease or disorder is fatty liver, hepatopathy, hepatic fibrosis, cirrhosis, hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, biliary atresia, or bile duct damage; the eye disease or disorder is cataract, or retinal degenerative disease (e.g., age-related macular degeneration, macular edema, retinopathy); the skin disease or disorder is skin aging, epidermal atrophy, loss of elasticity, wrinkles, nevi, macular edema, pigmentation, melasma, blemishes, hair loss, or wound healing disorders; the fibrotic disease or disorder is retroperitoneal fibrosis, idiopathic pulmonary fibrosis, pulmonary fibrosis, or liver fibrosis; The sclerosing disease or disorder is idiopathic pulmonary fibrosis or scleroderma; or other geriatric disease or disorder is frailty, sarcopenia, muscular dystrophy, lipoatrophy, age-related inflammation, or geriatric depression; or the side effects and sequelae of stress and the resulting age-related disease or disorder are fatigue, weakness, lethargy, weight loss, hepatotoxicity, nephrotoxicity, thrombosis, alopecia, or bone marrow dysfunction (e.g., myelodysplastic syndrome, myelopathy, bone marrow transplant disorder, anemia);A composition for removing senescent cells, wherein the rare disease is lipodystrophy, idiopathic pulmonary fibrosis, dementia with Lewy bodies, or non-alcoholic steatohepatitis.; 7. A composition for removing senescent cells in the fourth paragraph, wherein the disease or disorder associated with the senescent cells is cancer, inflammation, fibrosis, sclerosis, senescence, cognitive impairment, sarcopenia, osteoporosis, lipoatrophy, liver damage, kidney damage, skin aging, or a side effect of an anticancer drug or obesity.
8. A composition for removing senescent cells in the 7th paragraph, wherein the senescence is a decrease in activity, a decrease in endurance, a decrease in muscle strength, or a decrease in grip strength.
9. In the 7th paragraph, the skin aging is wrinkles, loss of elasticity, hair loss, deterioration of fur, freckles, blemishes, moles, spots, pigmentation, warts, hives, deterioration of pores, scars, or wound / damage healing disorder, a composition for removing senescent cells.
10. A composition for removing senescent cells, wherein the anticancer or antiobesity side effects are fatigue, weakness, weight loss, anxiety, depression, lethargy, or fatty liver.
11. A method for removing senescent cells, comprising contacting a therapeutically effective amount of a composition according to any one of claims 1 to 10 with senescent cells or administering or applying the composition to a subject in need of improvement, treatment, or prevention of a disease or disorder associated with senescent cells.
12. A method for removing senescent cells in claim 11, wherein the contact with the senescent cells is performed in vitro or ex vivo.
13. A method for removing senescent cells in accordance with claim 11, wherein the removal of senescent cells has an effect of improving, treating, or preventing diseases and disorders related to senescent cells.
14. A method for removing senescent cells according to any one of claims 11 to 13, wherein the method further comprises contacting senescent cells with at least one active ingredient selected from the group consisting of Roxadustat, Dexmedetomidine, 5-aminosalicylic acid, Pioglitazone, Rosiglitazone, Setanaxib, and an immune checkpoint inhibitor, or administering or applying the same to a subject in need of improvement, treatment, or prevention of a disease or disorder associated with senescent cells.
15. A method for removing senescent cells in claim 14, wherein the immune checkpoint inhibitor is at least one of a CTLA4 inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, and a PD-L2 inhibitor.
16. A composition according to any one of claims 1 to 10, and Containing at least one active ingredient selected from the group consisting of Roxadustat, Dexmedetomidine, 5-aminosalicylic acid, Pioglitazone, Rosiglitazone, Setanaxib, and immune checkpoint inhibitors. A kit or preparation for removing senescent cells.
Citation Information
Patent Citations
Cylindrical structure gas cabinet equipped with sliding doors that can be opened and closed and secured from the risk of explosion by using tempered glass and a cutout provided on the upper part
KR1020230018732A
Identification and elimination of damaged and / or senescent cells
US20200123607A1
KR20230068277A
Cited By
Application of Opaganib in preparation of anti-aging product
CN119700758A
C-17 carbonyl substituted oleanane triterpenoid derivative as well as preparation method and application thereof
CN119930733A
C-17 carbonyl-substituted esteran triterpenoid derivatives, methods of making and uses thereof
CN119930733B
Compositions and methods for treating or preventing neurodegenerative diseases
EP4540406A4
Crystalline form, and process for its production
US12703688B1
